Dr Goodwin

1974
Peer Review Committee, Washington Psychiatric Society, March 1974 to January 1976|
Visiting Professor, Department of Psychiatry, University of Wisconsin School of Medicine, Madison, Wisconsin, September 1976

Visiting Professor, Department of Psychiatry, Boston University, School of Medicine, Boston, Massachusetts, December 1976

Supporting Editor, Psychopharmacology, April 1976 to 1979

Editorial Advisory Board, Progress in Neuropsychopharmacology, Pergamon Press, New York, July 1976 to present

Editorial Board, Acta Neurologica, September 1977 to present

Visiting Professor, Department of Psychiatry, University of California,

School
of Medicine, Irvine, California, February 1977

Editorial Board, Archives of General Psychiatry, January 1978 to present

Board of Editorial Advisors, Progress in Psychiatric Drug Treatment, Brunner/Mazel, New York

Chairman, Committee on Problems of Public Concern, American College of Neuropsychopharmacology, January 1979 to December 1983

Founding Co-Editor-in-Chief, Psychiatry Research: International Journal for Rapid Communication, January 1979 to 1999

Visiting Professor, Department of Psychiatry, University of Southern

California
School of Medicine, February 1979

Guest Editor, Special Issue on Lithium, Archives of General Psychiatry, Volume 36, July 20, 1979

Chairman, Committee for the Protection of Human Subjects in Psychiatric Research, American Psychiatric Association, September 1979 to December 1982

Visiting Professor, Department of Psychiatry, Duke University, School of Medicine, November 1979 to 1994

Board of Scientific Advisors, Max Planck Institute for Psychiatry, Munich, Germany, 1979 to 1985

Nominating Committee, American College of Neuropsychopharmacology,

1979
to 1980
Editorial Board, Journal of Clinical Psychopharmacology, September 1980 to present

Editorial Board, Neuropsychobiology, 1983 to present

Consultant, Council on Research, American Psychiatric Association, May 1983 to 1988

Advisory Board for Clinical Research Training Program, Harvard Medical School, Department of Psychiatry, Massachusetts Mental Health Center, October 1984 to June 1988

Scientific Advisory Board of the American Friends of Jerusalem Mental Health Center, 1984 (indefinite)

Scientific Council, National Alliance for the Mentally Ill, 1984 to present

Nominating Committee, American College of Neuropsychopharmacology,

1984
to 1985
Group for the Advancement of Psychiatry (GAP), Committee on Research,

1985
Scientific Council, National Alliance for Research on Schizophrenia and Depression, August 1985 to present

National Academy of Sciences' Committee on Human Rights, November

1985
to present
Editorial Advisory Board, Human Psychopharmacology: Clinical and Experimental, 1985 to 1988 (3-year initial membership)

Editorial Advisory Board, Journal Club Psychiatry, 1985-1989

Advisory Board of the Pfizer Scholars Program for New Faculty, January 1986 to December 1987

Visiting Professor, Department of Psychiatry, University of Tennessee, School of Medicine, June 1986

National Alliance for the Mentally Ill (NAMI) National Advisory Board,

1986
Editorial Board, Ways for the Disabled, 1986 to 1988

Chairman of the Board, Dana London Sagalyn Fund, March 1987 to 1988

Chairman, Science Workgroup, Future of Psychiatry Conference, American Psychiatric Association, March through December 1987

Associate Editor, Journal of Neuropsychiatry and Clinical Neurosciences, 1988 to present

Visiting Professor, Pennsylvania State University, Hershey, Pennsylvania, March and April 1988 Visiting Professor, Medical College of Wisconsin, Milwaukee, Wisconsin, June 1988

Juror, Albert and Mary Lasker Medical Research Award, 1989

Co-Chair, Task Force on the Treatment of Depression in Primary Care, American Medical Association, 1989 to 1990

Co-Chair, Public Relations Committee, National Depressive and Manic- Depressive Association, 1989 to 1991

Institute of Medicine Membership Committee, National Academy of Sciences, representing Section 7, Psychiatry/Neurology; three-year term, 1989-1991

Editorial Board, Advances in Neuropsychiatry & Psychopharmacology, 1989 to 1992

Dialogue Advisory Board, Behavioral Healthcare Tomorrow, 1991

Scientific Advisory Board, National Depressive and Manic-DepressiveAssociation, 1991 to present

Executive Committee, National Depressive and Manic- Depressive Association, 1991-1992

Advisory Board, National Foundation for Brain Research, 1991 to 1995

Editorial Board, Journal of Psychiatric Research, 1991 to present

Task Force on Suicide, American College of Neuropsychopharmacology,

1991
International Kraepelin Medal Award Committee, 1992

Charter Member, Academia, Medicinae & Psyhchiatriae Foundation, Inc.,

1992
Consultant, Vestermark Award Board, Council on Internal Organization, American Psychiatric Association, May 1992 to 1993

President's Development Council, National Alliance for the Mentally Ill, 1992 to 2000

Editorial Advisory Board, Behavioral Healthcare Tomorrow, 1993 to present

Member, Board of Directors, Washington Foundation for Psychiatry, September 1994 to 2000

Resident Research Award Board, American Psychiatric Association/ Eli Lilly, 1995

Scientific Advisory Committee, Children's National Medical Center, Children's Research Institute, Washington, DC, January 1995 to January 1997

Committee on Relationships With Advocacy Groups, American College of Neuropsychopharmacology (ACNP), 1995-1998

Editorial Board, Synapse, 1995 to present

Scientific Advisory Council, American Foundation for Suicide Prevention, 1998 to present

Editorial Board, Understanding Stress, Anxiety and Depression; the International Journal of Mood Disorders, 1998 to present

Editorial Board, Bipolar Disorders: An International Journal of Psychiatry and Neurosciences, 1998 to present

Editorial Board, Clinical Approaches in Bipolar Disorders, 2002 to present

Governmental Appointments:
NIMH Clinical Research Review Board, 1970 to January 1981

Coordinator, Clinical Associate Orientation Program, Intramural Research Program, NIMH, 1971 to 1979

NIMH Clinical Investigations Coordinating Committee, including two subcommittees, 1975 to 1981

President, Assembly of Scientists, NIMH-NINCDS, December 1979 to March 1981

Chairman, Scientist Promotion Review Committee, NIMH Intramural Program, January 1980 to December 1982

Adjunct Professor of Pharmacology, Uniformed Services University of the Health Sciences (USUHS), School of Medicine, Bethesda, Maryland, January 1980 to 1988

Scholars Advisory Panel of the Scholars in Residence Program, Fogarty International Center, NIH, July 1984 to June 1988

The Secretary's Task Force on Suicide, Department of Health and Human Services, Washington, DC, 1985

Scientific Director, The National Depression Awareness, Recognition, and Treatment (D/ART) Program, NIMH, 1985

Coordinator of AIDS-related activities, Alcohol, Drug Abuse, and Mental Health Administration, 1986 to 1988

PHS Executive Task Force on AIDS (Chairman, Subgroup on Behavior, Addiction and Neuroscience), 1986-1988

NIH Patent Policy Board, April 1987 to 1992

Committee on NIH Scientific Faculty Proposal, Office of the Secretary, DHHS, May 1987 to 1992

Co-Chair, Public Health Service Work Group on Animal Welfare, 1989-1992

Co-Chair, Public Health Service Science Education Committee, 1989-1992

Federal Coordinating Committee on Science and Technology (FCCSET), Subcommittee on Human Resources, 1989-1992

AWARDS AND HONORS:

Who's Who in American Colleges and Universities, 1962-1963

Who's Who in America

A.E. Bennett Award for Clinical Research, presented by the Society of Biological Psychiatry, May 1970

Psychopharmacology Research Prize, presented by the American Psychological Association, September 1970

Hofheimer Prize for Research, presented by the American Psychiatric Association, May 1971

International Anna-Monika Prize for Research in Depression, June 1971

Taylor Manor Award, 1976

One of only five psychiatrists among Current Contents list of the 1,000 most frequently cited scientific authors worldwide (top 1/10 of 1 percent); listed as one of the world's most cited authors (less than one of 1 percent of all publishing researchers), 2002

Administrator's Award, ADAMHA, 1977

One of 12 psychiatrists listed in Best Doctors in the US, 1st and 2nd Editions, by John Pekkanen, Seaview Books, 1979 (and similar books by other publishers)

Public Health Service Superior Service Award, 1980

Senior Scientific Service Bonus, 1981

Senior Executive Service Presidential Rank Award ($10,000) (Meritorious Executive), 1982 (plus other Federal awards)

Senior Scientific Service Bonus, 1983

Edward A. Streckar Award, 1983

Senior Scientific Service Bonus, 1984

HHS Nomination for Presidential Rank Award (Distinguished Executive), 1984

University of North Carolina at Chapel Hill Distinguished Alumni Award,

Member, Institute of Medicine, National Academy of Sciences, 1985

Senior Executive Service Rank Award ($20,000) (Distinguished Executive), 1986

Senior Executive Association Professional Development League, Distinguished Executive Service Award of the Executive Excellence Awards PGM, 1986

DHHS Distinguished Service Award, 1987

Listed in the Town and Country Nationwide Referral Guide to the Best Psychotherapists, March 1988

The First Annual Psychiatrist of the Year Award (Best Teacher in Psychiatry),1989

Service to Science Award from the National Association for Biomedical Research, 1990

Public Service Award from the Federation of American Societies for Experimental Biology, 1990

Fawcett Humanitarian Award from the National Depressive and Manic- Depressive Association (NDMDA), 1990

St. Louis University Alumni Merit Award for Achievement in Biomedical Research, 1990

Association of American Publishers Award for Most Outstanding Book in the Biomedical Sciences, 1990, for Manic-Depressive Illness, with Kay R. Jamison (first psychiatry book to receive this award)

The Roy M. Grinker Visiting Professor of Psychiatry, Michael Reese Hospital, Detroit, Michigan, 1990

William R. McAlpin Research Achievement Award, 1991

Member, Alpha Omega Alpha Honor Medical Society, 1991

National Alliance for the Mentally Ill, Distinguished Service Award, 1994

Mathilde Soloway Award Lecture in the Neurosciences, Foundation for Advanced Education in the Sciences, Inc., NIH, 1994

Richard Simpson Memorial Award, Incurably Ill for Animal Research (iiFAR), 1994

The Harry Stack Sullivan Award, presented at Sheppard Pratt Hospital, Baltimore, MD, Keynote address on Scientific Day, March 25, 1995

Unity Award in Media for The Infinite Mind program on "Sleep," 1998.

The Unity Award in Media, Lincoln University of Missouri, for The Infinite Mind radio program, 1998, 1999 (3)

The National Headliner Award Honors for The Infinite Mind radio program, 1999; second place for (second place) for The Infinite Mind program on "Perfect Pitch," 2001; and for "Beyond the Baby Blues:Postpartum Depression and Psychosis" and "Mental Health in Troubled Times," 2002

EDI Awards for Excellence in Media, Easter Seal Society, for The Infinite Mind radio program, 1999 (3)

National Headliner Award for The Infinite Mind program on "Men and Suicide: The Tradegy of Timothy Hogan," 1999.

Clarion Award from the Association for Women in Communication for The Infinite Mind program on "Men and Suicide: The Tragedy of J. Timothy Hogan," 1999; "The Closing of Haverford State: A Special Report," 2000

Nominee, Research! AmericaÕs Advocacy Award for The Infinite Mind radio program, 1999

The Nola Maddox Falcone Prize, presented at the Gala Awards Dinner, New York, NY, Keynote address given at Scientific Dinner, October 14, 1999

Professor ad honorem, School of Medicine of Uruguay, 1999

WhoÕs Who in Science and Engineering, 2000

Deadline Club Award for "The Closing of Haverford State," awarded by Sigma Delta Chi, 2000

New York Press Club Best Feature Award for The Infinite Mind, 2000

Epilepsy Foundation Distinguished Journalism Award for The Infinite Mind program on "Epilepsy," 2000

Gracie Award from American Women in Television and Radio (honorable mention) for The Infinite Mind program on "PamÕs Story," 2001

National Headliner Award

International Radio Festival Award from the New York Festivals for The Infinite Mind program on "The Bipolar Child" 2001 Gracie Allen Award for "Mental Health in Troubled Times," 2002

HONORARY LECTURESHIPS (partial list):

Centennial Lectureship, University of North Carolina, School of Medicine, The first George C. Ham Memorial Lecture, University of North Carolina at Chapel Hill, 1984

David C. Wilson Lecture, University of Virginia at Charlottesville, 1985

Phineas J. Sparer Distinguished Lectureship in Psychiatry, University of Tennessee, Memphis, June 18-20, 1986

Theodore L. Dehne, M.D. Memorial Lecture, presented at the 15th Annual Friends Hospital Clinical Conference, October 1987

Invited Lecture, Third Vatican International Conference on Longevity and the Quality of Life ("Scientific Research at the Service of Longevity"), Rome, Italy, 1988

Invited Lecture, Fourth Vatican International Conference on Longevity and the Quality of Life ("Scientific Research at the Service of Longevity"), Rome, Italy, 1989

The John P. McGovern Award Lectureship presented at the Annual Meeting of the Association of Academic Health Centers, Naples, Florida October 5, 1990

The Herbert S. Ripley Lecture presented at the Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington April 24, 1991

Keynote Speaker, International Congress on Depressive Disorders ("Advances in the Understanding and Treatment of Recurrent Depression and Manic Depressive Illness") Melbourne, Australia July 1999

The 24th Annual Lebensohn Lecture presented at The Cosmos Club, Washington, D.C. October 23, 1999

AFFILIATIONS:

American Psychiatric Association (Distinguished Life Fellow, 1969)

American Association for the Advancement of Science

American Philosophical Association (currently inactive)

Washington Psychiatric

Society Society of Biological Psychiatry

American College of Neuropsychopharmacology (Fellow, 1970) American Academy of Psychoanalysis (currently inactive)

Society for Neuroscience

Psychiatric Research Society (President 1998-2000)

Collegium Internationale Neuro-Psychopharmacologicum (Fellow, 1972)

American Psychopathological Association

American Society of Clinical Psychopharmacology

Society for Light Treatment and Biological Rhythms

HIGHLIGHTS OF CLINICAL EXPERIENCE

The one constant throughout my otherwise varied professional career has been direct patient care. From 1965 to 1967, I was the primary clinician for inpatients on the Depression Treatment Unit at the NIMH/NIH Clinical Center. From 1967 to the present, my clinical work has been carried out through a part-time private practice. In this solo practice setting, I have evaluated and treated hundreds of patients over the years. Initially, I garnered considerable experience in individual long-term psychodynamic psychotherapy (much of it supervised by training psychoanalysts from the Washington School of Psychiatry), short term cognitive and behavioral psychotherapy, couples therapy, group therapy, and, of course, psychopharmacology. In recent years I have become more specialized in the evaluation and management (which includes psychotherapy) of patients with treatment-resistant depression and manic-depressive illness.

HIGHLIGHTS OF ADMINISTRATIVE EXPERIENCE

In May 1994, upon completing 30 years of Federal service, I left my post as Director, NIMH, to establish a Center on Neuroscience, Medical Progress and Society, at The George Washington University in Washington, D.C., where I am Research Professor of Psychiatry. The Center conducts clinical and services research and policy studies, examining -- from the perspectives of health care, the humanities, philosophy and law -- the impact on society of the behavioral and brain sciences. Among the initial, specific foci of the Center are issues facing psychiatry, including the impact of managed health care on quality of care, innovation, the doctor-patient relationship and confidentiality; the stigmatization of mental illness and the anti-science movementÕs focus on the behavioral and brain sciences; how concepts of human responsibility and free will can persevere as more is learned about brain function and behavior; and the implications of the Human Genome Project for treating and preventing disorders of behavior.

From 1992 to 1994, I directed the National Institute of Mental Health (NIMH). My return to the Institute permitted me to contribute to the historic reunion of the Institute with the National Institutes of Health (NIH). Key tasks during the transition included ensuring a continuing, productive association between the research and service sectors of the mental health field, the latter now the responsibility of the new Center for Mental Health Services in the Substance Abuse and Mental Health Services Administration (SAMHSA); serving as a lead HHS spokesman to the mental health field broadly and to the public regarding the aims and benefits of the reorganization; and drawing on my extensive NIMH/NIH experience to facilitate the reintroduction of NIMH programs into the NIH scientific and administrative milieu.

As Director of an Institute with a budget of $613 million (1994) and a staff of more than 1,300, 1,000 of whom are scientists, visiting scientists and support personnel in the Intramural Research Program, I was responsible for further strengthening the mental health research enterprise and for identifying strategies for and overseeing research-based assessments of clinical practice patterns, service system issues, and reimbursement policies germane to mental illness. Among my priorities were the accelerated implementation of "national plans" focused on schizophrenia, neuroscience, child and adolescent mental disorders, and research on the service need of persons with severe mental disorders; the Treatment Research Initiative; and ensuring that NIMH has continued to play an integral role in health care reform activities.

As Administrator of the Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA), I was responsible for Federal programs pertaining to mental illness, drug abuse, and alcoholism and for providing national leadership in meeting public health needs associated with these disorders. ADAMHAÕs mandate entailed dual responsibilities for supporting and conducting research and for enhancing the NationÕs specialty service systems for mental and addictive disorders. The AgencyÕs 1992 budget was $3.2 billion; of this amount, $1.3 billion was for the conduct and support of research and research training, and $1.9 billion supported service system improvement activities. ADAMHA employed some 2,000 permanent employees, with an additional 400 visiting scientists likely to be working in the AgencyÕs intramural research laboratories at any given time. As noted earlier, Congress reorganized ADAMHA in 1992, reuniting its three research institutes -- the National Institute on Alcohol Abuse and Alcoholism, the National Institute of Drug Abuse, and the National Institute of Mental Health -- with the NIH, and creating SAMHSA, dedicated to treatment and prevention-related service activities.

As Director of the NIMH Intramural Research Program (IRP), I was directly responsible for the largest mental health research program in the world. Comprised of some 20 branches/laboratories distributed across three campuses, the program conducts multidisciplinary research that ranges from the most fundamental neuroscience to clinical research on major mental illness to psychological and social studies of human development. The IRP, with what was then an annual budget of some $60 million, employed 600 people, of whom just under half are scientists and, additionally, hosted several hundred guest scientists. Closely linked to its research mission is the programÕs role as the nationÕs largest single resource for research training in mental health and neuroscience research. In addition to managing and providing leadership to the NIMH/IRP, I was a member of the NIH Board of Scientific Directors, through which I participated in the formulation of NIH policy governing intramural research.

For three years I served on the HHS Departmental work group assigned to reevaluate and draft regulations for the Protection of Human Subjects of Research. Prior to this, I represented the Institute in its interactions with the National Commission for the Protection of Human Subjects, giving testimony, preparing draft reports, and generally contributing to policy formulation.

HIGHLIGHTS OF TEACHING EXPERIENCE

At the Washington School of Psychiatry, I designed and taught an Advanced Seminar in Psychopharmacology, which focused on the psychodynamics of drug administration, including the combined use of psychoactive drugs and analytic therapy.

At The George Washington University Medical Center, I have participated in curriculum planning for psychiatry at the medical student and resident levels. I also a conduct monthly case conference and serve as a mentor for psychiatric residents taking a research elective. I have given lectures in psychiatry and psychopharmacology to medical students, graduate students, and residents.

I am frequently invited to lecture at universities here and abroad to conduct special teaching programs for practicing physicians, to give public lectures, and to participate in the efforts of the mass media to understand psychiatry and research in neurobiology. Recent presentations include Columbia University, Cornell University, Duke University, UCLA, University of California San Diego, the Menninger Foundation and Clinic, University of Chicago, University of Pennsylvania, Boston University, Yale University, The Mayo Clinic, Harvard University, University of Naples, Italy, University of Utrecht, the Netherlands, University of San Paulo, Brazil, University of Munich, Germany, the Peking Medical College and the Shanghai First Medical College of the PeopleÕs Republic of China, the Karolinska Institute, Stockholm, and many others.

As Co-Chair of the American Medical AssociationÕs Task Force on the Treatment of Depression in Primary Care, I convened a group of specialists in the treatment of depression and leaders of the primary care community to outline a training program in this area, to be run under AMA auspices.

Public addresses include the Smithsonian Institution lecture series, the NIH medicine for the Layman series, the Annual Meetings of the National Mental Health Association, the Philosophical Society of Washington, the National Alliance for the Mentally Ill, and many others.

I was invited by the Chinese Medical Association to lecture at psychiatric facilities in China in June 1980; other members of the seven-person delegation included the Director of NIMH and the President, President-Elect, and Medical Director of the American Psychiatric Association. I also served as a member of the U.S.-Peoples Republic of China Joint Health Committee in November 1980, and in this capacity I returned to China to participate in the final negotiations and shaping of the U.S.-China Health Agreements.

HIGHLIGHTS OF PUBLIC EDUCATION/ADVOCACY EXPERIENCE

The challenge of translating -- making our professional and scientific language and concepts both interesting and understandable to the public -- has intrigued me throughout my career. I have indeed been fortunate that my positions over the years have afforded me ample opportunity to put my belief in the importance of public education into practice. Not too many years ago, a commitment to public education was clearly against the grain among my scientific colleagues. I am pleased that that is much less the case today.

From the mid-1980Õs on, I worked with various advocacy groups especially the National Alliance for the Mentally Ill (NAMI), the Mental Health Association, and the National Depressive and Manic-Depressive Association (which I helped make into a national organization) in a wide variety of destigmatization efforts. Early on, I recognized the unique value of pairing patients with professionals in these activities, an approach which has subsequently become widely used. At one point, I formed a private Foundation to fund depression education programs for college students, an activity that was subsequently incorporated into NAMI. Many of the educational/advocacy activities in which I was involved were conducted on Capitol Hill for obvious reasons.

I worked with Dr. Kay Jamison in the production of two Moods and Music concerts, the first at UCLA and the second at the Kennedy Center with the National Symphony Orchestra, which became a highly successful television special. Other activities have included conducting special workshops for reporters at scientific meetings and providing frequent off-the-record background interviews with reporters and writers working on various stories and features.

As host of the award-winning The Infinite Mind since 1998, a one hour weekly public radio program heard nationwide on over 175 stations, I have had the opportunity to educate the public about the brain, behavioral sciences, and about mental illness.

SCIENCE EDUCATION EXPERIENCE

From 1989 -1992, I represented the Department of Health and Human Services on the Human Resources Subcommittee Federal Coordinating Committee on Science and Technology (FCCSET) and served as founder and Co-Chair of the Public Health Service (PHS) Science Education Committee. I created and implemented the Science Education Partnership Award (SEPA), a novel grant that supports partnerships among working scientists and primary/secondary school teachers. The SEPA program was subsequently adopted by the NIH.

In speaking extensively about impediments to scientific literacy, and in advocating programs to improve public understanding of science, and for improved communications by scientists about their work, I worked closely with the National Association of Biology Teachers, the Science Teachers Association and the Biological Sciences Curriculum Study (BSCS).

I co-directed the NIMH/Library of Congress Decade of the Brain Symposium Series for the Public. Other relevant activities include the Smithsonian lecture series, the NIH "Medicine for the Layman" Series, the Philosophical Society of Washington and numerous presentations to lay audiences on mental illness and neuroscience research. I frequently appeared in the print and broadcast media to defend biomedical research, often in a debate format with animal rights advocates. In association with this, I received formal media training, which has developed my communications skills beyond the level of most of my research colleagues.

BOOKS:

1. Wehr TA, Goodwin FK, eds: Circadian Rhythms in Psychiatry. Pacific Grove, CA: The Boxwood Press, 1983.

2. Goodwin FK, Jamison KR, eds: Bipolar Disorders. In: RE Hales, AJ Frances, eds: Psychiatry Update: The American Psychiatric Association Annual Review, Vol 6. Washington, DC: American Psychiatric Press, Inc, 1987.

3. Nerozzi D, Goodwin FK, Costa E, eds: Advances in Biochemical Psychopharmacology. Vol. 43. Hypothalamic Dysfunction in Neuropsychiatric Disorders. New York: Raven Press, 1987.

4. Goodwin FK, Jamison KR: Manic-Depressive Illness. New York: Oxford University Press, 1990. (Best Medical Book Award from the Association of American Publishers.)

JOURNAL ARTICLES AND BOOK CHAPTERS:

1. Weissbach H, Goodwin FK, Maxwell ES: The effect of steroids on aldehyde oxidation: Studies with indoleacetaldehyde. Biochem Biophys Acta 49: 384- 387, 1961.

2. Renson J, Goodwin F, Weissbach H, Udenfriend S: Conversion of tryptophan to 5-hydroxytryptophan by phenylalanine hydroxylase. Biochem Biophys Res Comm 6:20-23, 1961.

3. Hollender MH, Goodwin FK, Fleiss AN, Butz JL, Mariner AS, Kaplan EA, Hunt WL, Pearl NH: The compensation problem. Int Psychiat Clin 2:583-602, 1965.

4. Hollender MH, Hirsch SJ, Goodwin FK, Kaplan EA, Rubert SL, Watkins ES, Walker L, Steckler PP, Albaugh JK, Ripich LJ: Schizophrenia or temporal lobe disorder? Int Psychiat Clin 2:667-689, 1965.

5. Colburn RW, Goodwin FK, Bunney WE Jr, Davis JM: Effect of lithium on the uptake of noradrenaline by synaptosomes. Nature 215:1395-1397, 1967.

6. Bunney WE Jr, Goodwin FK, Davis JM, Fawcett JA: A behavioral-biochemical study of lithium treatment. Am J Psychiatry 125:499-512, 1968.

7. Greenspan K, Goodwin FK, Bunney WE Jr, Durell J: Lithium ion retention and distribution: Patterns during acute mania and normothymia. Arch Gen Psychiatry 19:664-673, 1968.

8. Colburn RW, Goodwin FK, Murphy DL, Bunney WE Jr, Davis JM: Quantitative studies of norepinephrine uptake by synaptosomes. Biochem Pharmacol 17: 957-964, 1968.

9. Goodwin FK, Shafritz D, Weissbach H: In vitro polypeptide synthesis in brain. Arch Biochem Biophys 130:183-190, 1969.

10. Shafritz D, Goodwin F, Weissbach H: Inhibition by aminochromes of in vitro polypeptide synthesis in Escherichia coli. Arch Biochem Biophys 134:478-485, 1969.

11. Goodwin FK, Murphy DL, Bunney WE Jr: Lithium-carbonate treatment in depression and mania: A longitudinal double-blind study. Arch Gen Psychiatry 21: 486-496, 1969.

12. Bunney WE Jr, Janowsky DW, Goodwin FK, Davis JM, Brodie HKH, Murphy DL, Chase TN: Effect of L-dopa on depression. Lancet i:885-886, 1969.

13. Goodwin FK, Murphy DL, Bunney WE Jr: Lithium. Lancet ii:212-213, 1969.

14. Murphy DL, Goodwin FK, Bunney WE Jr: Aldosterone and sodium response to lithium administration in man. Lancet ii:458-461, 1969.

15. Goodwin FK, Brodie HKH: The combined use of L-dopa and peripheral decarboxylase inhibitor (MK 485) in depression. Ann Intern Med 72:806, 1970.

16. Goodwin FK, Murphy DL, Brodie HKH, Bunney WE Jr: L-dopa, catecholamines, and behavior: A clinical and biochemical study in depressed patients. Biol Psychiatry 2:341-366, 1970. (AE Bennett Prize Paper)

17. Bunney WE Jr, Murphy DL, Brodie HKH, Goodwin FK: L-dopa in depressed patients. Lancet i:352, 1970.

18. Goodwin FK, Brodie HKH, Murphy DL, Bunney WE Jr: Administration of a peripheral decarboxylase inhibitor with L-dopa to depressed patients. Lancet i:908-911, 1970.

19. Paul MI, Cramer H, Goodwin FK: Urinary cyclic AMP in affective illness. Lancet i:996, 1970.

20. Bunney WE Jr, Murphy DL, Goodwin FK, Borge GF: The switch process from depression to mania: Relationship to drugs which alter brain amines. Lancet i:1022-1027, 1970.

21. Tamarkin NR, Goodwin FK, Axelrod J: Rapid elevation of biogenic amine metabolites in human CSF following probenecid. Life Sci 9:1397-1408, 1970.

22. Fram DH, Murphy DL, Goodwin FK, Brodie HKH, Bunney WE Jr, Snyder F: L- dopa and sleep in depressed patients. Psychophysiology 7:316-317, 1970.

23. Brodie HKH, Murphy DL, Goodwin FK, Bunney WE Jr: Alpha-methyl-para- tyrosine in affective illness. In: O Vinar, Z Voltava, PB Bradley, eds: Advances in Neuropsychopharmacology: Proceedings of the 7th Congress of the Collegium Internationale Neuro-Psychopharmacologicum. Amsterdam: North-Holland, 1971. pp 141-144.

24. Bunney WE Jr, Brodie HKH, Murphy DL, Goodwin FK: Studies of alpha- methyl-para-tyrosine, L-dopa, and L-tryptophan in depression and mania. Am J Psychiatry 127:872-881, 1971.

25. Murphy DL, Goodwin FK, Bunney WE Jr: Leucocytosis during lithium treatment. Am J Psychiatry 127:1559-1561, 1971.

26. Buchsbaum M, Goodwin F, Murphy D, Borge G: AER in affective disorders. Am J Psychiatry 128:19-25, 1971.

27. Paul MI, Cramer H, Goodwin FK: Urinary cyclic AMP in depression and mania: Effects of levodopa and lithium carbonate. Arch Gen Psychiatry 24:327-333, 1971.

28. Borge GF, Buchsbaum M, Goodwin F, Murphy D, Silverman J: Neuropsychological correlates of affective disorders. Arch Gen Psychiatry 24:501-504, 1971.

29. Gershon ES, Dunner DL, Goodwin FK: Toward a biology of affective disorders: Genetic contributions. Arch Gen Psychiatry 25:1-15, 1971.

30. Dunner DL, Cohn CK, Gershon ES, Goodwin FK: Differential catechol-O- methyl- transferase activity in unipolar and bipolar affective illness. Arch Gen Psychiatry 25:348-353, 1971.

31. Gershon ES, Bunney WE Jr, Goodwin FK, Murphy DL, Dunner DL, Henry GM: Catecholamines and affective illness: Studies with L-dopa and alpha-methyl-para-tyrosine. In: BT Ho, WM McIsaac, eds: Brain Chemistry and Mental Disease. Vol. 1. New York: Plenum Press, 1971. pp 135-161.

32. Dunner DL, Brodie HKH, Goodwin FK: Plasma dopa response to levodopa administration in man: Effects of a peripheral decarboxylase inhibitor. Clin Pharmacol Ther 12:212-217, 1971.

33. Brodie HK, Murphy DL, Goodwin FK, Bunney WE Jr: Catecholamines and mania: The effect of alpha-methyl-para-tyrosine on manic behavior and catecholamine metabolism. Clin Pharmacol Ther 12:218-224, 1971.

34. Goodwin FK, Murphy DL, Brodie HKH, Bunney WE Jr: Levodopa: Alterations in behavior. Clin Pharmacol Ther 12:383-396, 1971.

35. Murphy DL, Goodwin FK, Bunney WE Jr: Clinical and pharmacological investigations of the psychobiology of the affective disorders. Int Pharmacopsychiatry 6:137-146, 1971.

36. Goodwin FK: Psychiatric side effects of levodopa in man. JAMA 218:1915- 1920, 1971.

37. Goodwin FK, Dunner DL, Gershon ES: Effect of L-dopa treatment on brain serotonin metabolism in depressed patients. Life Sci 10:751-759, 1971.

38. Murphy DL, Brodie HK, Goodwin FK, Bunney WE Jr: Regular induction of hypomania by L-dopa in "bipolar" manic-depressive patients. Nature 229:135-136, 1971.

39. Goodwin FK, Bunney WE Jr: Depressions following reserpine: A reevaluation. Semin Psychiatry 3:435-448, 1971.

40. Goodwin FK: Behavioral effects of L-dopa in man. Semin Psychiatry 3:477- 492, 1971.

41. Dunner DL, Goodwin FK, Gershon ES, Murphy DL, Bunney WE Jr: Excretion of 17-OCHS in unipolar and bipolar depressed patients. Arch Gen Psychiatry 26:360-363, 1972.

42. Dunner DL, Goodwin FK: Effect of L-tryptophan on brain serotonin metabolism in depressed patients. Arch Gen Psychiatry 26:364-366, 1972.

43. Bunney WE Jr, Murphy DL, Goodwin FK, Borge GF: The "switch process" in manic-depressive illness: I. A systematic study of sequential behavior changes. Arch Gen Psychiatry 27:295-302, 1972.

44. Bunney WE Jr, Goodwin FK, Murphy DL, House KM, Gordon EK: The "switch process" in manic-depressive illness: II. Relationship to catecholamines, REM sleep, and drugs. Arch Gen Psychiatry 27:304-309, 1972.

45. Bunney WE Jr, Goodwin FK, Murphy DL: The "switch process" in manic- depressive illness: III. Theoretical implications. Arch Gen Psychiatry 27:312- 317, 1972.

46. Goodwin FK, Murphy DL, Dunner DL, Bunney WE Jr: Lithium response in unipolar versus bipolar depression. Am J Psychiatry 129:44-47, 1972.

47. Kotin J, Goodwin FK: Depression during mania: Clinical observations and theoretical implications. Am J Psychiatry 129:679-686, 1972.

48. Goodwin FK, Bunney WE Jr: The biology of bipolar affective illness: Studies with L-dopa and alpha-methyl-para-tyrosine. In: S Gershon, chair, 10th Annual American College of Neuropsychopharmacology symposium: Amines and Affective Disorders. Psychopharmacol Bull 8(4):33-34, 1972.

49. Goodwin FK, Post RM: Problems in the study of amine turnover in man - the probenecid technique. In: WE Bunney Jr, chair, 10th Annual American College of Neuropsychopharmacology symposium: Methods for the Study of Amine Function in Man. Psychopharmacol Bull 8(4):12-13, 1972.

50. Post RM, Kotin J, Matzen M, Jones CC, Goodwin FK: Effect of serum from depressed and manic patients on maze behavior of rats. Experientia 28:1471- 1472, 1972.

51. Murphy DL, Goodwin FK, Bunney WE Jr: A reevaluation of biogenic amines in manic and depressive states. Hosp Prac 7:85-92, 1972.

52. Bunney WE Jr, Gershon ES, Murphy DL, Goodwin FK: Psychobiological and pharmacological studies of manic-depressive illness. J Psychiatr Res 9:207-226, 1972.

53. Cramer H, Goodwin FK, Post RM, Bunney WE Jr: Effects of probenecid and exercise on cerebrospinal-fluid cyclic A.M.P. in affective illness. Lancet i:1346- 1347, 1972.

54. Ebert MH, Post RM, Goodwin FK: Effect of physical activity on urinary MHPG excretion in depressed patients. Lancet ii:766, 1972.

55. Bunney WE Jr, Goodwin FK, Murphy DL: Some current psychobiological studies of the effects of L-dopa in depressive and manic-depressive patients. In : S Malitz, ed: L-dopa and Behavior. New York: Raven Press, 1972. pp 87-102.

56. Goodwin FK, Ebert MH, Bunney WE Jr: Mental effects of reserpine in man: A review. In: RI Shader, ed: Psychiatric Complications of Medical Drugs. New York: Raven Press, 1972. pp 73-101.

57. Goodwin FK: Behavioral effects of L-dopa in man. In: RI Shader, ed: Psychiatric Complications of Medical Drugs. New York: Raven Press, 1972. pp 149-174.

58. Murphy DL, Goodwin FK, Bunney WE Jr: Electrolyte changes in the affective disorders: Problems of specificity and significance. In: TA Williams, MM Katz, JA Shield, eds: Recent Advances in the Psychobiology of the Depressive Illnesses. Washington, DC: US Government Printing Office, 1972. pp 59-70.

59. Post RM, Kotin J, Goodwin FK, Gordon EK: Psychomotor activity and cerebrospinal fluid amine metabolites in affective illness. Am J Psychiatry 130:67-72, 1973.

60. Goodwin FK, Post RM, Dunner DL, Gordon EK: Cerebrospinal fluid amine metabolites in affective illness: The probenecid technique. Am J Psychiatry 130:73-79, 1973.

61. Murphy DL, Goodwin FK, Brodie HKH, Bunney WE Jr: L-dopa, dopamine, and hypomania. Am J Psychiatry 130: 79-82, 1973.

62. Kotin J, Post RM, Goodwin FK: Drug treatment of depressed patients referred for hospitalization. Am J Psychiatry 130:1139-1141, 1973.

63. Carlson GA, Goodwin FK: The stages of mania: A longitudinal analysis of the manic episode. Arch Gen Psychiatry 28:221-228, 1973.

64. Kotin J, Post RM, Goodwin FK: Delta-9-tetrahydrocannabinol in depressed patients. Arch Gen Psychiatry 28:345-348, 1973.

65. Gershon ES, Dunner DL, Sturt L, Goodwin FK: Assortative mating in the affective disorders. Biol Psychiatry 7:63-74, 1973.

66. Buchsbaum M, Landau S, Murphy DL, Goodwin FK: Average evoked response in bipolar and unipolar affective disorders: Relationship to sex, age of onset, and monoamine oxidase. Biol Psychiatry 7: 199-212, 1973.

67. Post RM, Goodwin FK: Simulated behavior states: An approach to specificity in psychobiological research. (AE Bennett Award Paper.) Biol Psychiatry 7:237- 254, 1973.

68. Gillin JC, Post RM, Wyatt RJ, Goodwin FK, Snyder F, Bunney WE Jr: REM inhibitory effect of L-dopa infusion during human sleep. Electroencephalogr Clin Neurophysiol 35:181-186, 1973.

69. Goodwin FK, Sack RL: Affective disorders: The catecholamine hypothesis revisited. In: E Usdin, SH Snyder eds: Frontiers in Catecholamine Research. New York: Pergamon Press, 1973. pp 1157-1164.

70. Goodwin FK, Ebert M: Lithium in mania: Clinical trials and controlled studies. In: S Gershon, B Shopsin, eds: Lithium: Its Role in Psychiatric Research and Treatment. New York: Plenum Press, 1973. pp 237-252.

71. Gordon EK, Oliver J, Goodwin FK, Chase T, Post RM: Effect of probenecid on free 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) and its sulfate in human cerebrospinal fluid. Neuropharmacology 12:391-396, 1973.

72. Goodwin FK, Bunney WE Jr: A psychobiological approach to affective illness. Psychiatr Ann 3:19-53, 1973.

73. Post RM, Gordon EK, Goodwin FK, Bunney WE Jr: Central norepinephrine metabolism in affective illness: MHPG in the cerebrospinal fluid. Science 179:1002-1003, 1973.

74. Post RM, Goodwin FK, Gordon E, Watkin DM: Amine metabolites in human cerebrospinal fluid: Effects of cord transection and spinal fluid block. Science 179:897-899, 1973.

75. Goodwin FK, Bunney WE Jr: Psychobiological aspects of stress and affective illness. In: JP Scott, EC Senay, eds: Separation and Depression. Washington, DC: American Association for the Advancement of Science, 1973. pp 91-112.

76. Goodwin FK, Post RM: The use of probenecid in high doses for the estimation of central serotonin turnover in affective illness and addicts on methadone. In: J Barchas, E Usdin, eds: Serotonin and Behavior. New York: Academic Press, 1973. pp 469-480.

77. Goodwin FK, Post RM: Brain serotonin, affective illness and antidepressant drugs: Cerebrospinal fluid studies with probenecid. In : E Costa, GL Gessa, M Sandler, eds: Advances in Biochemical Psychopharmacology. Vol 11: Serotonin - New Vistas: Biochemistry and Behavioral and Clinical Studies. New York: Raven Press, 1974. pp 341-355.

78. Ablon SL, Goodwin FK: High frequency of dysphoric reactions to tetrahydrocannabinol among depressed patients. Am J Psychiatry 131:448-453, 1974.

79. Post RM, Kotin J, Goodwin FK: The effects of cocaine on depressed patients. Am J Psychiatry 131:511-517, 1974.

80. Ablon SL, Carlson GA, Goodwin FK: Ego defense patterns in manic-depressive illness. Am J Psychiatry 131:803-807, 1974.

81. Post RM, Goodwin FK: Effects of Amitriptyline and imipramine on amine metabolites in the cerebrospinal fluid of depressed patients. Arch Gen Psychiatry 30:234-239, 1974.

82. Sack RL, Goodwin FK: Inhibition of dopamine-beta-hydroxylase in manic patients: A clinical trial with fusaric acid. Arch Gen Psychiatry 31:649-654, 1974.

83. Beckmann H, Jones C, Goodwin FK: Unterschiedliche Ausscheidung von 3- Methoxy-4-hydroxyphenylglycol im Urin und Ansprechen auf trizyklische Antidepressiva. Arzneimittel-Forschung 24:1010-1012, 1974.

84. Goodwin FK, Sack RL: Behavioral effects of new dopamine-beta-hydroxylase inhibitor (fusaric acid) in man. J Psychiatr Res 11:211-217, 1974.

85. Carman JS, Post RM, Teplitz TA, Goodwin FK: Letter: Divalent cations in predicting antidepressant response to lithium. Lancet ii:1454, 1974.

86. Goodwin FK, Sack RL: Central dopamine function in affective illness: Evidence from precursors, enzyme inhibitors, and studies of central dopamine turnover. In: E Usdin: Neuropsychopharmacology of Monoamines and Their Regulatory Enzymes. New York: Raven Press, 1974. pp 261-279.

87. Goodwin FK: Summary. In: IS Forrest, CJ Carr, E Usdin, eds: Phenothiazines and Structurally Related Drugs. New York: Raven Press, 1974. pp 799-804.

88. Goodwin FK: On the biology of depression. In: RJ Friedman, MM Katz, eds: The Psychology of Depression: Contemporary Theory and Research. Washington, DC: VH Winston & Sons, 1974. pp 240-251.

89. Murphy DL, Baker M, Goodwin FK, Miller H, Kotin J, Bunney WE Jr: L- tryptophan in affective disorders: Indoleamine changes and differential clinical effects. Psychopharmacologia (Berlin) 34:11-20, 1974.

90. Post RM, Gillan JC, Wyatt RJ, Goodwin FK: The effect of orally administered cocaine on sleep of depressed patients. Psychopharmacologia (Berlin) 37:59-66, 1974.

91. Goodwin FK, Murphy DL: Biological factors in the affective disorders and schizophrenia. In: M Gordon, ed: Psychopharmacological Agents. Vol 3. New York: Academic Press, 1974. pp 9-37.

92. Post RM, Goodwin FK: Estimation of brain amine metabolism in affective illness: Cerebrospinal fluid studies utilizing probenecid. Psychother Psychosom 23:142- 158, 1974.

93. Murphy DL, Goodwin FK, Bunney WE Jr: The psychobiology of mania. In: D Hamburg, HKH Brodie, eds: American Handbook of Psychiatry. Vol. 6. New York: Basic Books, 1975. pp 502-532.

94. Goodwin FK, Murphy DL: Biological factors in the major psychoses. Annual Reports in Medicinal Chemistry 10: 39-50, 1975.

95. Beckmann K, Goodwin FK: Antidepressant response to tricyclics and urinary MHPG in unipolar patients: Clinical response to imipramine or amitriptyline. Arch Gen Psychiatry 32:17-21, 1975.

96. Post RM, Fink E, Carpenter WT, Goodwin FK: Cerebrospinal fluid amine metabolites in acute schizophrenia. Arch Gen Psychiatry 32:1063-1069, 1975.

97. Goodwin FK, Post RM: Studies of amine metabolites in affective illness and in schizophrenia: A comparative analysis. In: DX Freedman, ed: Biology of the Major Psychoses: A Comparative Analysis. Research Publications: Association for Research in Nervous and Mental Disease. Vol. 54. New York: Raven Press, 1975. pp 299-332.

98. Jimerson DC, Gordon EK, Post RM, Goodwin FK: Central noradrenergic function in man: Vanillylmandelic acid in CSF. Brain Res 99:434-439, 1975.

99. Goodwin FK, Sack RL: Behavioral effects of a new dopamine-beta-hydroxylase inhibitor (fusaric acid) in man. In: SW Matthysse, SS Kety, eds, Catecholamines and Schizophrenia. New York: Pergamon Press, 1975. pp 211-217.

100. Belmaker R, Beckmann H, Goodwin F, Murphy D, Pollin W, Buchsbaum M, Wyatt R, Ciaranello R, Lamprecht F: Relationships between platelet and plasma monoamine oxidase, plasma dopamine-beta-hydroxylase, and urinary 3-methoxy-4-hydroxyphenylglycol. Life Sci 16: 273-280, 1975.

101. Goodwin FK, Post RM, Sack RL: Clinical evidence for neurochemical adaptation to psychotropic drugs. In: AJ Mandell, ed: Neurobiological Mechanisms of Adaptation and Behavior. New York: Raven Press, 1975. pp 33-45.

102. Claeys M, Muscettola G, Goodwin FK, Markey SP: Simultaneous measurement of plasma levels of imipramine and desipramine in patients with primary affective disorders. In: ER Klein, DP Klein, eds: Proceedings of the Second International Conference on Stable Isotopes. Springfield, VA: National Technical Information Service, US Department of Commerce 1975. pp 198-207.

103. Goodwin FK, Post RM, Jimerson D: Studies of CSF amine metabolites in affective illness and in schizophrenia. M Airaksinen, ed: Proceedings of the Sixth International Congress of Pharmacology: Vol 3. CNS and Behavioral Pharmacology. Oxford: Pergamon Press, 1975. pp 285-297.

104. Post RM, Goodwin FK: Studies of cerebrospinal fluid amine metabolites in depressed patients: Conceptual problems and theoretical implications. In: J Mendels, ed: The Psychobiology of Depression. New York: Spectrum Publications, New York, 1975. pp 47-67.

105. Beckmann H, St.-Laurent J, Goodwin FK: The effect of lithium on urinary MHPG in unipolar and bipolar depressed patients. Psychopharmacologia (Berlin) 42:277-282, 1975.

106. Lipton MA, Goodwin FK: A controlled study of thyrotropin releasing hormone in hospitalized depressed patients. Psychopharmacol Bull 11:8-29, 1975.

107. Goodwin FK, Post RM: Cerebrospinal fluid amine metabolites in affective illness and schizophrenia: Clinical and pharmacological studies. Psychopharmocol Commun 1:641-653, 1975.

108. Post RM, Goodwin FK: Time-dependent effects of phenothiazines on dopamine turnover in psychiatric patients. Science 190:488-489, 1975.

109. Carman JS, Post RM, Buswell R, Goodwin FK: Negative effects of melatonin on depression. Am J Psychiatry 133:1181-1186, 1976.

110. Kopin IJ, Kaufman S, Viveros H, Jacobowitz D, Lake CR, Ziegler MG, Lovenberg W, Goodwin FK: Dopamine-beta-hydroxylase: Basic and clinical studies. Ann Int Med 85:211-223, 1976.

111. Post RM, Kotin J, Goodwin FK: Effects of sleep deprivation on mood and central amine metabolism in depressed patients. Arch Gen Psychiatry 33:627-632, 1976.

112. Dunner DL, Gershon ES, Goodwin FK: Heritable factors in the severity of affective illness. Biol Psychiatry 11:31-42, 1976.

113. Beckmann H, van Kammen DP, Goodwin FK, Murphy DL: Urinary excretion of 3-methoxy-4-hydroxyphenylglycol in depressed patients: Modifications by amphetamine and lithium. Biol Psychiatry 11:377-387, 1976.

114. St.-Laurent J, Roizen MF, Beckmann H, Miliaressis E, Goodwin FK, Jacobowitz DM: Neurochemical changes in discrete areas of the rat brain after self- stimulation from the area ventralis tegmenti. In: A Wanquier, ET Rolls, eds: Brain-Stimulation Reward. Amsterdam: North-Holland Publishing Company, 1976. pp 283-289.

115. Chodoff P, Goodwin FK: Depression: Psychotherapy or pharmacotherapy? J Am Acad Psychoanalysis 4:275-277, 1976.

116. Donnelly EF, Murphy DL, Goodwin FK: Cross-sectional and longitudinal comparisons of bipolar and unipolar depressed groups on the MMPI. J Consult and Clin Psychol 44:233-237, 1976.

117. Gold PW, Goodwin FK, Wehr T, Rebar R, Sack R: Growth-hormone and prolactin response to levodopa in affective illness [letter]. Lancet ii:1308-1309, 1976.

118. Goodwin FK, Wehr T, Sack RL: Studies on the mechanism of action of lithium in man: A contribution to neurobiological theories of affective illness. In: A Villeneuve, ed: Lithium in Psychiatry: A Synopsis. Quebec: Les Presses de LÕUniversitŽ Laval, 1976. pp 23-48.

119. Jimerson DC, Post RM, Goodwin FK: Antidepressant treatments and alterations in central serotonin turnover in affective illness. Monographs in Neural Sciences 3: 15-22, 1976.

120. Davenport YB, Ebert MH, Adland ML, Goodwin FK: Couples group therapy as an adjunct to lithium maintenance of the manic patient. Am J Orthopsychiatry 47:495-502,1977.

121. Muscettola G, Wehr T, Goodwin FK: Effect of diet on urinary MHPG excretion in depressed patients and normal control subjects. Am J Psychiatry 134:914- 916, 1977.

122. Gold PW, Goodwin FK, Wehr T, Rebar R: Pituitary thyrotropin response to thyrotropin-releasing hormone in affective illness: Relationship to spinal fluid amine metabolites. Am J Psychiatry 134:1028-1031, 1977.

123. Goodwin FK: Pharmacologic studies: Lithium and other antimanic drugs. pp 329-331, In: Bunney WE Jr (Moderator): "The switch process in manic depressive psychosis," Ann Int Med 87:319-335, 1977.

124. Carman JS, Post RM, Goodwin FK, Bunney WE Jr: Calcium and electroconvulsive therapy of severe depressive illness. Biol Psychiatry 12:5-17, 1977.

125. Major LF, Ballenger JC, Goodwin FK, Brown GL: Cerebrospinal fluid homovanillic acid in male alcoholics: Effect of disulfiram. Biol Psychiatry 12:635-642, 1977.

126. Goodwin FK, Post RM, Wehr T: Clinical approaches to the evaluation of brain amine function in mental illness: Some conceptual issues. In: MBH Youdim, W Lovenberg, DF Sharman, JR Lagnado, eds: Essays in Neurochemistry and Neuropharmacology. Vol 2. Chichester: John Wiley and Sons, 1977. pp 71- 104.

127. Wehr T, Goodwin FK: Catecholamines in depression. In: GD Burrows, ed: Handbook of Studies on Depression. Amsterdam: Excerpta Medica, 1977. pp 283-301.

128. Marangos PJ, Zomzely-Neurath C, Goodwin FK: Structural and immunological properties of neuron specific protein (NSP) from rat, cat and human brain: Comparison to bovine 14-3-2. J Neurochem 28:1097-1107, 1977.

129. Davis KL, Hollister LE, Goodwin FK, Gordon EK: Neurotransmitter metabolites in the cerebrospinal fluid of man following physostigmine. Life Sci 21:933-936, 1977.

130. Goodwin FK, Post RM: Catecholamine metabolite studies in the affective disorders: Issues of specificity and significance. In: E Usdin, DA Hamburg, JD Barchas, eds: Neuroregulators and Psychiatric Disorders. New York: Oxford University Press, 1977. pp 135-145.

131. Post RM, Goodwin FK, Cramer H: Cyclic adenosine monophosphate in cerebrospinal fluid in patients with affective illness: Effects of probenecid, activity, and psychotropic medications. In: E Usdin, DA Hamburg, JD Barchas, eds: Neuroregulators and Psychiatric Disorders. New York: Oxford University Press, 1977. pp 464-469.

132. Goodwin FK, Cowdry R, Gold PW, Wehr T: Central monoamine metabolism in depression and mania. In: HM van Praag, J Bruinvels, eds: Neurotransmission and Disturbed Behavior. Amsterdam: De Erven Bohn BV, 1977. pp 34-59.

133. Post RM, Cramer H, Goodwin FK: Cyclic AMP in cerebrospinal fluid of manic and depressive patients. Psychol Med 7:599-605, 1977.

134. Goodwin FK: Diagnosis of affective disorders. In: ME Jarvik, ed: Psychopharmacology in the Practice of Medicine. New York: Appleton- Century-Crofts, 1977. pp 219-228.

135. Goodwin FK: Biologic basis of drug action in the affective disorders. In: M Jarvik, ed: Psychopharmacology in the Practice of Medicine. New York: Appleton-Century-Crofts, 1977. pp 231-238.

136. Goodwin FK: Drug treatment of affective disorders: General principles. In: M Jarvik, ed: Psychopharmacology in the Practice of Medicine. New York: Appleton-Century-Crofts, 1977. pp 241-253.

137. Goodwin FK, Ebert MH: Specific antimanic and antidepressant drugs. In: M Jarvik, ed: Psychopharmacology in the Practice of Medicine. New York: Appleton-Century-Crofts, 1977. pp 257-273.

138. Goodwin FK, Ebert MH: Recent advances in drug treatment of affective disorders. In: M Jarvik, ed: Psychopharmacology in the Practice of Medicine. New York: Appleton-Century-Crofts, 1977. pp 277-287.

139. Donnelly EF, Goodwin FK, Waldman IN, Murphy DL: Prediction of antidepressant responses to lithium. Am J Psychiatry 135:552-556, 1978.

140. Post RM, Lake CR, Jimerson DC, Bunney WE Jr, Wood JH, Ziegler MG, Goodwin FK: Cerebrospinal fluid norepinephrine in affective illness. Am J Psychiatry 135:907-912, 1978.

141. Gold MS, Redmond DE Jr, Donabedian RK, Goodwin FK, Extein I: Increase in serum prolactin by exogenous and endogenous opiates: Evidence for antidopamine and antipsychotic effects. Am J Psychiatry 135:1415-1416, 1978.

142. Post RM, Gerner RH, Carman JS, Gillin JC, Jimerson DC, Goodwin FK, Bunney WE Jr: Effects of a dopamine agonist piribedil in depressed patients: Relationship of pretreatment homovanillic acid to antidepressant response. Arch Gen Psychiatry 35:609-615, 1978.

143. Muscettola G, Goodwin FK, Potter WZ, Claeys MM, Markey SP: Imipramine and desipramine in plasma and spinal fluid: Relationship to clinical response and serotonin metabolism. Arch Gen Psychiatry 35:621-625, 1978.

144. Goodwin FK, Webster MH, Post RM: Cerebrospinal fluid amine metabolites in affective illness and schizophrenia: Clinical and pharmacological studies. In: E Usdin, AJ Mandell, eds: Biochemistry of Mental Illness: New Vistas. New York: Marcel Dekker, 1978. pp 165-189.

145. Lerner P, Goodwin FK, van Kammen DP, Post RM, Major LF, Ballenger JC, Lovenberg W: Dopamine-beta-hydroxylase in the cerebrospinal fluid of psychiatric patients. Biol Psychiatry 13:685-694, 1978.

146. Marangos PJ, Goodwin FK, Parma A, Lauter C, Trams E: Neuron specific protein (NSP) in neuroblastoma cells: Relation to differentiation. Brain Res 145: 49-58, 1978.

147. Marangos PJ, Zis AP, Clark RL, Goodwin FK: Neuronal, non-neuronal and hybrid forms of enolase in brain: Structural, immunological and functional comparisons. Brain Res 150:117-133, 1978.

148. Jimerson DC, Gordon EK, Post RM, Goodwin FK: Homovanillic acid in human CSF: Comparison of fluorimetry and gas chromatography-mass spectrometry. Comm in Psychopharmacol 2:343-349, 1978.

149. Cowdry RW, Goodwin FK: Amine neurotransmitter studies and psychiatric illness: Toward more meaningful diagnostic concepts. In: R Spitzer, DF Klein, eds: Critical Issues in Psychiatric Diagnosis. New York: Raven Press 1978. pp 281-304.

150. Goodwin FK, Potter WZ: The biology of affective illness: Amine neurotransmitters and drug response. In: JO Cole, AF Schatzberg, SH Frazier, eds: Depression: Biology, Dynamics and Treatment. New York: Plenum Press, 1978. pp 41-73.

151. Post RM, Goodwin FK: Approaches to brain amines in psychiatric patients: A reevaluation of cerebrospinal fluid studies. In: LL Iversen, SD Iversen, SH Snyder, eds: Handbook of Psychopharmacology, Vol 13: Biology of Mood and Antianxiety Drugs. New York: Plenum Press, 1978. pp 147-185.

152. Donnelly EF, Murphy DL, Goodwin FK: Primary affective disorder: Anxiety in unipolar and bipolar depressed groups. J Clin Psychol 34: 621-623, 1978.

153. Marangos PJ, Parma AM, Goodwin FK: Functional properties of neuronal and glial isoenzymes of brain enolase. J Neurochem 31: 727-732, 1978.

154. Potter WZ, Goodwin FK: Antidepressant drug levels and clinical response. [letter] Lancet i:1049-1050, 1978.

155. Gold PW, Goodwin FK, Reus VI: Vasopressin in affective illness. Lancet i:1233-1236, 1978.

156. Marangos PJ, Paul SM, Greenlaw P, Goodwin FK, Skolnick P: Demonstration of an endogenous, competitive inhibitor(s) of [_H] diazepam binding in bovine brain. Life Sci 22:1893-1900, 1978.

157. Skolnick P, Marangos PJ, Goodwin FK, Edwards M, Paul S: Identification of inosine and hypoxanthine as endogenous inhibitors of [_H] diazepam binding in the central nervous system. Life Sci 23:1473-1480, 1978.

158. Goodwin FK, Extein IL, Wehr TA: Some recent advances in psychobiology and psychopharmacology of affective disorders. In: FJ Ayd, IJ Taylor, eds: Mood Disorders: The WorldÕs Major Public Health Problem. Baltimore: Ayd Medical Communications, 1978. pp 22-43.

159. Goodwin FK, Muscettola G, Gold PW, Wehr T: Biochemical and pharmacological differentiation of affective disorder. In: HS Akiskal, WL Webb, eds: Psychiatric Diagnosis: Exploration of Biological Predictors. New York: SP Medical and Scientific Books, 1978. pp 313-336.

160. Lipton MA, Carlsson A, Dunner DL, Goodwin FK, Janowsky DS, Meltzer HY, Wyatt RJ: Biochemical and pharmacological predictors. In: HS Akiskal, WL Webb, eds: Psychiatric Diagnoses: Exploration of Biological Predictors. New York: SP Medical and Scientific Books, 1978. pp 337-362.

161. Goodwin FK, Cowdry RW, Webster MH: Predictors of drug response in the affective disorders: Toward an integrated approach. In: MA Lipton, A DiMascio, KF Killam, eds: Psychopharmacology: A Generation of Progress. New York: Raven Press, 1978. pp 1277-1288.

162. Potter WZ, Zavadil AP, Goodwin FK: Prediction of steady-state plasma concentration of imipramine. Psychopharmacol Bull 14:29-33, 1978.

163. Schmechel D, Marangos PJ, Zis AP, Brightman M, Goodwin FK: Brain enolases as specific markers of neuronal and glial cells. Science 199:313-315, 1978.

164. Wehr TA, Goodwin FK: Biological rhythms and affective illness. In: FF Flach, ed: Weekly Psychiatry Update Series. Vol 2. New York: Biomedia, Inc, 1978. pp 1-7.

165. Davenport YB, Adland ML, Gold PW, Goodwin FK: Manic-depressive illness: Psychodynamic features of multigenerational families. Am J Orthopsychiatry 49:24-35, 1979.

166. Gold PW, Davenport YB, Wehr T, Goodwin FK: The impact of normal volunteers on a psychiatric research unit. Am J Psychiatry 136:401-405, 1979.

167. Extein I, Potter WZ, Wehr TA, Goodwin FK: Rapid mood cycles after a noradrenergic but not a serotonergic antidepressant. Am J Psychiatry 136:1602- 1603, 1979.

168. Skolnick P, Goodwin FK, Paul SM: A rapid and sensitive radioreceptor assay for benzodiazepine in plasma. Arch Gen Psychiatry 36:78-80, 1979.

169. Ballenger JC, Goodwin FK, Major LF, Brown GL: Alcohol and central serotonin metabolism in man. Arch Gen Psychiatry 36:224-227, 1979.

170. Wehr TA, Goodwin FK: Rapid cycling in manic-depressives induced by tricyclic antidepressants. Arch Gen Psychiatry 36:555-559, 1979.

171. Goodwin FK: The lithium ion: Impact on treatment and research: Introduction. Arch Gen Psychiatry 36:833-834, 1979.

172. Zis AP, Goodwin FK: Major affective disorder as a recurrent illness: A critical review. Arch Gen Psychiatry 36:835-839, 1979.

173. Goodwin FK, Zis AP: Lithium in the treatment of mania: Comparisons with neuroleptics. Arch Gen Psychiatry 36: 840-844, 1979.

174. Jamison KR, Gerner RH, Goodwin FK: Patient and physician attitudes toward lithium: Relationship to compliance. Arch Gen Psychiatry 36:866-869, 1979.

175. Zis AP, Goodwin FK: Novel antidepressants and the biogenic amine hypothesis of depression: The case for iprindole and mianserin. Arch Gen Psychiatry 36:1097-1107, 1979.

176. Jimerson DC, Post RM, Carman JS, van Kammen DP, Wood JH, Goodwin FK, Bunney WE Jr: CSF calcium: Clinical correlates in affective illness and schizophrenia. Biol Psychiatry 14:37-51, 1979.

177. Major LF, Lerner P, Ballenger JC, Brown GL, Goodwin FK, Lovenberg W: Dopamine-beta-hydroxylase in the cerebrospinal fluid: Relationship to disulfiram-induced psychosis. Biol Psychiatry 14:337-344, 1979.

178. Marangos PJ, Schmechel D, Zis AP, Goodwin FK: The existence and neurobiological significance of neuronal and glial forms of the glycolytic enzyme enolase. Biol Psychiatry 14:563-579, 1979.

179. Potter WZ, Calil HM, Manian AA, Zavadil AP, Goodwin FK: Hydroxylated metabolites of tricyclic antidepressants: Preclinical assessment of activity. Biol Psychiatry 14:601-613, 1979.

180. Lewy AJ, Wehr TA, Gold PW, Goodwin FK: Melatonin secretion in manic- depressive illness. In: T Obiols, C Ballœs, E Gonz‡les Monclœs, J Pujol, eds: Biological Psychiatry Today. Amsterdam: Elsevier/North Holland, 1979. pp 563-565.

181. Wehr TA, Wirz-Justice A, Lewy AJ, Goodwin FK: Biological rhythm disturbances in affective illness. In: T Obiols, C Ballœs, E Gonz‡les Monclœs, J Pujol, eds: Biological Psychiatry Today. Amsterdam: Elsevier/North Holland, 1979. pp 612-614.

182. Potter WZ, Calil HM, Manian A, Goodwin FK: Hydroxylated metabolites of tricyclic antidepressants: Inhibition of amine uptake and other pre-clinical studies. In: E Usdin, IJ Kopin, J Barchas, eds: Catecholamines: Basic and Clinical Frontiers. Vol 1. New York: Pergamon Press, 1979. pp 373-375.

183. Lewy AJ, Wehr TA, Gold PW, Goodwin FK: Plasma melatonin in manic- depressive illness. In: E Usdin, IJ Kopin, J Barchas, eds: Catecholamines: Basic and Clinical Frontiers. Vol 2. New York: Pergamon Press, 1979. pp 1173-1175.

184. Gold PW, Ballenger J, Zis AP, Robertson G, Post RM, Goodwin FK: A vasopressin hypothesis of affective illness: Preliminary findings. In: E Usdin, IJ Kopin, J Barchas, eds: Catecholamines: Basic and Clinical Frontiers. Vol. 2. New York: Pergamon Press, 1979. pp 1176-1178.

185. Goodwin FK, Potter WZ: Norepinephrine metabolite studies in affective illness. In: E Usdin, IJ Kopin, J Barchas, eds: Catecholamines: Basic and Clinical Frontiers. Vol 2. New York: Pergamon Press, 1979. pp 1863-1865.

186. Post RM, Jimerson DC, Reus VI, Goodwin FK, Silberman E, Bunney WE Jr: Dopaminergic agents in affective illness: Studies with piribedil, amphetamine, and pimozide. In: E Usdin, IJ Kopin, J Barchas, eds: Catecholamines: Basic and Clinical Frontiers. Vol 2. New York: Pergamon Press, 1979. pp 1899-1901.

187. Wehr T, Goodwin FK: Tricyclics modulate frequency of mood cycles. Chronobiologia 6:377-385, 1979.

188. Extein I, Goodwin FK, Lewy AJ, Schoenfeld RI, Fakhuri LR, Gold MS, Redmond DE Jr: Behavioral and biochemical effects of FK 33-824, a parenterally and orally active enkephalin analogue. In: E Usdin, WE Bunney Jr, NS Kline, eds: Endorphins in Mental Health Research. New York: Oxford University Press, 1979. pp 279-292.

189. Buchsbaum MS, Carpenter WT Jr, Fedio P, Goodwin FK, Murphy DL, Post RM: Hemispheric differences in evoked potential enhancement by selective attention to hemiretinally presented stimuli in schizophrenic, affective and post-temporal lobectomy patients. In: J Gruzelier, P Flor-Henry, eds: Hemisphere Asymmetries of Function in Psychopathology. Amsterdam: Elsevier, 1979. pp 317-328.

190. Marangos PJ, Schmechel D, Parma AM, Clark RL, Goodwin FK: Measurement of neuron-specific (NSE) and non-neuronal (NNE) isoenzymes of enolase in rat, monkey and human nervous tissue. J Neurochem 33:319-329, 1979.

191. Gold PW, Weingartner H, Ballenger JC, Goodwin FK, Post RM: Effects of 1- desamo-8-D-arginine vasopressin on behavior and cognition in primary affective disorder. Lancet ii:992-994, 1979.

192. Marangos PJ, Paul SM, Parma AM, Goodwin FK, Syapin P, Skolnick P: Purinergic inhibition of diazepam binding to rat brain (in vitro). Life Sci 24:851-858, 1979.

193. Marangos PJ, Paul SM, Goodwin FK, Skolnick P: Putative endogenous ligands for the benzodiazepine receptor. Life Sci 25:1093-1102, 1979.

194. Nurnberger JI, Gershon ES, Murphy DL, Buchsbaum MS, Goodwin FK, Post RM, Lake CR, Guroff JJ, McGiniss MH: Biological and clinical predictors of lithium response in depression. In: TB Cooper, S Gershon, NS Kline, M Schou, eds: Lithium: Controversies and Unresolved Issues. Amsterdam: ExcerptaMedica, 1979. pp 241-256.

195. Goodwin FK, Zis AP: Lithium in mania: Comparisons with neuroleptics and the issue of specificity. In: TB Cooper, S Gershon, NS Kline, M Schou, eds: Lithium: Controversies and Unresolved Issues. Amsterdam: Excerpta Medica, 1979. pp 282-303.

196. Zis AP, Grof P, Goodwin FK: The natural course of affective disorders: Implications for lithium prophylaxis. In: T Cooper, S Gershon, NS Kline, M Schou, eds: Lithium: Controversies and Unresolved Issues. Amsterdam: Exerpta Medica, 1979. pp 381-398.

197. Buchsbaum MS, Lavine RA, Davis GC, Goodwin FK, Murphy DL, Post RM: Effects of lithium on somatosensory evoked potentials and prediction of clinical response in patients with affective illness. In: TB Cooper, S Gershon, NS Kline, M Schou, eds: Lithium: Controversies and Unresolved Issues. Amsterdam: Excerpta Medica, 1979. pp 685-702.

198. Donnelly EF, Murphy DL, Waldman IN, Goodwin FK: Prediction of antidepressant responses to imipramine. Neuropsychobiology 5:94-101, 1979.

199. Goodwin FK, Potter WZ: Noradrenergic function in affective illness. In: B Saletu, P Berner, L Hollister, eds: Neuro-Psychopharmacology. New York: Pergamon Press, 1979. pp 127-137.

200. Ballenger JC, Post RM, Sternberg DE, van Kammen DP, Cowdry RW, Goodwin FK: Headaches after lumbar puncture and insensitivity to pain in psychiatric patients. N Engl J Med 301:110, 1979.

201. Potter WZ, Zavadil AP, Goodwin FK: Prediction of steady-state plasma concentration of imipramine. In: LA Gottschalk, ed: Pharmacokinetics of Psychoactive Drugs: Further Studies. New York: Spectrum Publications, 1979. pp 37-48.

202. Skolnick P, Marangos PJ, Syapin P, Goodwin FK, Paul SM: CNS benzodiazepine receptors: Physiological studies and putative endogenous ligands. Pharmacol Biochem Behav 10:815-823, 1979.

203. Beckmann H, Ebert MH, Post R, Goodwin FK: Effect of moderate exercise on urinary MHPG in depressed patients. Pharmakopsychiatr Neuropharmakol 12:351-356, 1979.

204. Goodwin FK, Extein IL: The biological basis of affective disorders. In: R Cancro, L Shapiro, M Kesselman, eds: Progress in the Functional Psychoses. New York: Spectrum Publications, 1979. pp 129-152.

205. Zis AP, Cowdry RW, Wehr TA, Muscettola G, Goodwin FK: Tricyclic-induced mania and MHPG excretion. Psychiatry Res 1:93-99, 1979.

206. Brown GL, Goodwin FK, Ballenger JC, Goyer PF, Major LF: Aggression in humans correlates with cerebrospinal fluid amine metabolites. Psychiatry Res 1:131-139, 1979.

207. Extein I, Tallman J, Smith CC, Goodwin FK: Changes in lymphocyte beta- adrenergic receptors in depression and mania. Psychiatry Res 1:191-197, 1979.

208. Potter WZ, Calil HM, Extein I, Zavadil AP, Goodwin FK: Comparative pharmacokinetics of zimelidine and desipramine in man following acute and chronic administration. Psychiatry Res 1: 273-281, 1979.

209. Extein I, Lo C, Goodwin FK, Schoenfeld RI: Dopamine-mediated behavior produced by the enkephalin analogue FK 33-824. Psychiatry Res 1:333-339, 1979.

210. Potter WZ, Muscettola G, Goodwin FK: Binding of imipramine to plasma protein and to brain tissue: Relationship to CSF tricyclic levels in man. Psychopharmacology 63:187-192, 1979.

211. Wehr TA, Goodwin FK: Rapid cycling between mania and depression caused by maintenance tricyclics. Psychopharmacol Bull 15:17-19, 1979.

212. Brown GL, Ballenger JC, Minichiello MD, Goodwin FK: Human aggression and its relationship to cerebrospinal fluid 5-hydroxyindoleacetic acid, 3-methoxy-4-hydroxyphenylglycol, and homovanillic acid. In: M Sandler, ed: Psychopharmacology of Aggression. New York: Raven Press, 1979. pp 131-148.

213. Wehr TA, Wirz-Justice A, Goodwin FK, Duncan W, Gillin JC: Phase advance of the circadian sleep-wake cycle as an antidepressant. Science 206:710-713, 1979.

214. Davis GC, Extein I, Reus VI, Hamilton W, Post RM, Goodwin FK, Bunney WE Jr: Failure of naloxone to reduce manic symptoms. Am J Psychiatry 137:1583-1585, 1980.

215. Wehr TA, Muscettola G, Goodwin FK: Urinary 3-methoxy-4- hydroxyphenylglycol circadian rhythm: Early timing (phase-advance) in manic- depressives compared with normal subjects. Arch Gen Psychiatry 37:257-263, 1980.

216. Extein I, Pottash ALC, Gold MS, Sweeney DR, Martin DM, Goodwin FK: Deficient prolactin response to morphine in depressed patients. Am J Psychiatry 137:845-846, 1980.

217. Gold PW, Extein I, Pickar D, Rebar R, Ross R, Goodwin FK: Suppression of plasma cortisol in depressed patients by acute intravenous methadone infusion. Am J Psychiatry 137:862-863, 1980.

218. Major LF, Lerner P, Goodwin FK, Ballenger JC, Brown GL, Lovenberg WP: Dopamine-beta-hydroxylase in CSF: Relationship to personality measures. Arch Gen Psychiatry 37:308-310, 1980.

219. Potter WZ, Zavadil AP, Kopin IJ, Goodwin FK: Single-dose kinetics predict steady-state concentrations of imipramine and desipramine. Arch Gen Psychiatry 37:314-320, 1980.

220. Paul SM, Marangos PJ, Goodwin FK, Skolnick P: Brain-specific benzodiazepine receptors and putative endogenous benzodiazepine-like compounds. Biol Psychiatry 15:407-428, 1980.

221. Marangos PJ, Schmechel DE, Parma AM, Goodwin FK: Developmental profile of neuron-specific (NSE) and non-neuronal (NNE) enolase. Brain Res 190:185- 193, 1980.

222. Post RM, Ballenger JC, Hare TA, Goodwin FK, Lake CR, Jimerson DC, Bunney We Jr: Cerebrospinal fluid GABA in normals and patients with affective disorders. Brain Res Bull 5(Suppl 2):755-759, 1980.

223. Buchsbaum MS, Davis GC, Goodwin FK, Murphy DL, Post RM: Psychophysical pain judgments and somatosensory evoked potentials in patients with affective illness and normal adults. In: C Perris, L van Knorring, eds: Clinical Neurphysiological Aspects of Psychopathological Conditions. Basel, Switzerland: S Karger AG, 1980. pp 63-72.

224. Gold PW, Goodwin FK, Ballenger JC, Weingartner H, Robertson GL, Post RM: Central vasopressin function in affective illness. In: D de Wied, PA van Keep, eds: Hormones and the Brain. Baltimore: University Park Press, 1980. pp 241- 252.

225. Donnelly EF, Waldman IN, Murphy DL, Wyatt RJ, Goodwin FK: Primary affective disorder: Thought disorder in depression. J Abnorm Psychol 89:315- 319, 1980.

226. Lewy AJ, Tetsuo M, Markey SP, Goodwin FK, Kopin IJ: Pinealectomy abolishes plasma melatonin in the rat. J Clin Endocrinol Metab 50:204-205, 1980.

227. Marangos PJ, Campbell IC, Schmechel DE, Murphy DL, Goodwin FK: Blood platelets contain a neuron-specific enolase subunit. J Neurochem 34:1254-1258, 1980.

228. Paul SM, Rehavi M, Skolnick P, Goodwin FK: Demonstration of specific "high affinity" binding sites for [_H] imipramine on human platelets. Life Sci 26:953- 959, 1980.

229. Rehavi M, Paul SM, Skolnick P, Goodwin FK: Demonstration of specific high affinity binding sites for [_H] imipramine in human brain. Life Sci 26:2273- 2279, 1980.

230. Ebert MH, Kartzinel R, Cowdry RW, Goodwin FK: Cerebrospinal fluid amine metabolites and the probenecid test. In: JH Wood, ed: The Neurobiology of Cerebrospinal Fluid. Vol 1. New York: Plenum Press, 1980. pp 97-112.

231. Post RM, Ballenger JC, Goodwin FK: Cerebrospinal fluid studies of neurotransmitter function in manic and depressive illness. In: JH Wood, ed: The Neurobiology of Cerebrospinal Fluid. Vol 1. New York: Plenum Press, 1980. pp 685-717.

232. Hays SE, Beinfeld MC, Jensen RT, Goodwin FK, Paul SM: Demonstration of a putative receptor site for cholecystokinin in rat brain. Neuropeptides 1:53-62, 1980.

233. Beckman H, Goodwin FK: Urinary MHPG in subgroups of depressed patients and normal controls. Neuropsychobiology 6:91-100, 1980.

234. Crawley J, Goodwin FK: Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 13:167- 180, 1980.

235. Rosenthal NE, Davenport Y, Cowdry RW, Webster MH, Goodwin FK: Monoamine metabolites in cerebrospinal fluid of depressive subgroups. Psychiatry Res 2:113-119, 1980.

236. Paul SM, Marangos PJ, Skolnick P, Goodwin FK: Brain-specific benzodiazepine receptors and putative endogenous "benzodiazepine-like" compounds. Psychopharmacol Bull 16:9-20, 1980.

237. Wehr TA, Goodwin FK: Desynchronization of circadian rhythms as a possible source of manic-depressive cycles. Psychopharmacol Bull 16:19-20, 1980.

238. Potter WZ, Calil HM, Zavadil AP, Jusko WJ, Sutfin T, Rapoport JL, Goodwin FK: Steady-state concentrations of hydroxylated metabolites of tricyclic antidepressants in patients: Relationship to clinical effect. Psychopharmacol Bull 16:32-34, 1980.

239. Gold PW, DeFraites E, Zis AP, van Kammen DP, Goodwin FK: The LH response to dopamine infusion: Possible marker for central dopaminergic function in psychiatric patients. Psychopharmacol Bull 16:36-38, 1980.

240. Gillin JC, Sitaram N, Duncan WC, Gershon ES, Nurnberger J, Post RM, Murphy DL, Wehr T, Goodwin FK, Bunney WE Jr: Sleep disturbance in depression: Diagnostic potential and pathophysiology. Psychopharmacol Bull 16:40- 42,1980.

241. Wirz-Justice A, Wehr TA, Goodwin FK, Kafka MS, Naber D, Marangos PJ, Campbell IC: Antidepressant drugs slow circadian rhythms in behavior and brain neurotransmitter receptors. Psychopharmacol Bull 16:45-47, 1980.

242. Zis AP, Grof P, Webster M, Goodwin FK: Prediction of relapse in recurrent affective disorder. Psychopharmacol Bull 16:47-49, 1980.

243. Post RM, Jimerson DC, Bunney WE Jr, Goodwin FK: Dopamine and mania: Behavioral and biochemical effects of the dopamine receptor blocker pimozide. Psychopharmacology (Berlin) 67:297-305, 1980.

244. Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, Markey SP: Light suppresses melatonin secretion in humans. Science 210:1267-1269, 1980.

245. Potter WZ, Calil HM, Extein I, Gold PW, Wehr TA, Goodwin FK: Specific norepinephrine and serotonin uptake inhibitors in man: A crossover study with pharmacokinetic, biochemical, neuroendocrine and behavioral parameters. Acta Psychiatr Scand Suppl 290:152-165, 1981.

246. Gold PW, Post RM, Weingartner H, Goodwin FK: Central peptide function in affective illness: Arginine vasopressin as a model system. In: J Mendlewicz, A Coppen, HM van Praag, eds: Advances in Biological Psychiatry. Vol 7. Depressive Illness: Biological and Psychopharmacological Issues. Basel, Switzerland: S Karger, 1981. pp 1-16.

247. Post RM, Ballenger JC, Jimerson DC, Goodwin FK, Gold PW, Lerner P, Bunney WE Jr: Cerebrospinal fluid amines and peptides in affective illness. In: B Angrist, GD Burrows, M Lader, O Lingjaerde, G Sedwall , D Wheatley, eds: Advances in the Biosciences. Vol 31. Recent Advances in Neuropsycho-Pharmacology. New York: Pergamon Press, 1981. pp 275-282.

248. Post RM, Bunney WE Jr, van Kammen DP, Ballenger JC, Lake CR, Lerner P, Sternberg DE, Uhde TW, Goodwin FK: Cerebrospinal fluid norepinephrine and dopamine-beta-hydroxylase in affective illness and schizophrenia. In: B Angrist, GD Burrows, M Lader, O Lingjaerde, G Sedwall, D Wheatley, eds: Advances in the Biosciences. Vol 31. Recent Advances in Neuropsycho-Pharmacology. New York: Pergamon Press, 1981. pp 283-287.

249. Wehr TA, Goodwin FK: Biological rhythms and psychiatry. In: S Arieti, HKH Brodie, eds: American Handbook of Psychiatry: Vol. 7, Advance and New Directions. 2nd ed. New York: Basic Books, 1981. pp 46-74.

250. Pickar D, Davis GC, Schulz SC, Extein I, Wagner R, Naber D, Gold PW, van Kammen DP, Goodwin FK, Wyatt RJ, Li CH, Bunney WE Jr: Behavioral and biological effects of acute beta-endorphin injection in schizophrenic and depressed patients. Am J Psychiatry 138:160-166, 1981.

251. Paul SM, Extein I, Calil HM, Potter WZ, Chodoff P, Goodwin FK: Use of ECT with treatment-resistant depressed patients at the National Institute of Mental Health. Am J Psychiatry 138:486-489, 1981.

252. Cowdry RW, Goodwin FK: Dementia of bipolar illness: Diagnosis and response to lithium. Am J Psychiatry 138:1118-1119, 1981.

253. Naber D, Pickar D, Post RM, van Kammen DP, Waters RN, Ballenger JC, Goodwin FK, Bunney WE Jr: Endogenous opioid activity and beta-endorphin immunoreactivity in CSF of psychiatric patients and normal volunteers. Am J Psychiatry 138:1457-1462, 1981.

254. Paul SM, Rehavi M, Skolnick P, Ballenger JC, Goodwin FK: Depressed patients have decreased binding of tritiated imipramine to platelet serotonin "transporter." Arch Gen Psychiatry 38:1315-1317, 1981.

255. Rehavi M, Ittah Y, Rice KC, Skolnick P, Goodwin FK, Paul SM: 2- Nitroimipramine: A selective irreversible inhibitor of [_H] serotonin uptake and [_H] imipramine binding in platelets. Biochem Biophys Res Comm 99:954-959, 1981.

256. Paul SM, Rehavi M, Skolnick P, Goodwin FK: [_H] imipramine binding to the serotonin "transporter" in human brain and platelet: A possible biological marker in depression. In: E Usdin, I Hanin, eds: Biological Markers in Psychiatry and Neurology. Oxford: Pergamon Press, 1981. pp 193-204.

257. Sotsky SM, Lake CR, Goodwin FK: Adrenocortical function and plasma norepinephrine in normal human subjects. Biol Psychiatry 16:643-651, 1981.

258. Post RM, Rubinow DR, Gold PW, Ballenger JC, Goodwin FK, Pickar D, Naber D, Uhde TW, Reichlin S, Bollinger J, Bunney WE Jr: Somatostatin and opiate peptides in CSF of affectively ill patients: Effects of carbamazepine. In: C Perris, G Struwe, B Jansson, eds: Biological Psychiatry 1981. Amsterdam: Elsevier, 1981. pp 345-348.

259. Hays SE, Goodwin FK, Paul SM: Cholecystokinin receptors are decreased in basal ganglia and cerebral cortex of HuntingtonÕs disease. Brain Res 225:452- 456, 1981.

260. Paul SM, Rehavi M, Hulihan B, Skolnick P, Goodwin FK: A rapid and sensitive radioreceptor assay for tertiary amine tricyclic antidepressants. Comm Psychopharmacol 4:487-494, 1981.

261. Goodwin FK: The impact of antidepressant treatment on the course of recurrent affective disorders. In: G Tognoni, C Bellantuono, M Lader, eds: Epidemiological Impact of Psychotropic Drugs. New York: Elsevier/North Holland Biomedical Press, 1981. pp. 221-235.

262. Patel J, Marangos PJ, Goodwin FK: [_H] Ethyl-beta-carboline-3-carboxylate binding to the benzodiazepine receptor is not affected by GABA. Europ J Pharmacol 72:419-420, 1981.

263. Cowdry RW, Goodwin FK: Biological and physiological predictors of drug response. In: HM van Praag, MH Lader, OJ Rafaelsen, EJ Sachar, eds: Handbook of Biological Psychiatry, Part VI: Practical Applications of Psychotropic Drugs and Other Biological Treatments. New York: Marcel Dekker, Inc, 1981. pp 263-308.

264. Gold PW, Goodwin FK, Ballenger JC, Post RM, Weingartner H, Robertson GL: Central vasopressin function in affective illness. Int J Mental Health 9:91-107, 1981.

265. Parma AM, Marangos PJ, Goodwin FK: A more sensitive radioimmunoassay for neuron-specific enolase suitable for cerebrospinal fluid determinations. J Neurochem 36:1093-1096, 1981.

266. Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, Rosenthal NE: Manic- depressive patients may be supersensitive to light [letter]. Lancet i:384, 1981.

267. Zis AP, Gold PW, Paul SM, Goodwin FK, Murphy DL: Elevation of human plasma and platelet amine oxidase activity in response to intravenous dopamine. Life Sci 28:371-376, 1981.

268. Marangos PJ, Patel J, Hirata F, Sondhein D, Paul SM, Skolnick P, Goodwin FK: Inhibition of diazepam binding by tryptophan derivatives including melatonin and its brain metabolites N-acetyl-5-methoxy kynurenamine. Life Sci 29:259- 267, 1981.

269. Crews FT, Paul SM, Goodwin FK: Acceleration of beta-receptor desensitization in combined administration of antidepressants and phenoxybenzamine. Nature 290: 787-789, 1981.

270. Buchsbaum MS, Muscettola G, Goodwin FK: Urinary MHPG, stress response, personality factors and somatosensory evoked potentials in normal subjects and patients with major affective disorders. Neuropsychobiology 7:212-224, 1981.

271. Hays SE, Goodwin FK, Paul SM: Cholecystokinin receptors in brain: Effects of obesity, drug treatment, and lesions. Peptides 2 (Suppl 1): 21-26,1981. 272. Crawley JN, Hays SE, OÕDonohue TL, Paul SM, Goodwin FK: Neuropeptide modulation of social and exploratory behaviors in laboratory rodents. Peptides 2 (Suppl 1):123-129, 1981.

273. Crawley JN, Hays SE, Paul SM, Goodwin FK: Cholecystokinin reduces exploratory behavior in mice. Physiol and Behav 27:407-411, 1981.

274. Gillin JC, Duncan WC, Murphy DL, Post RM, Wehr TA, Goodwin FK, Wyatt RJ, Bunney WE Jr: Age-related changes in sleep in depressed and normal subjects. Psychiatry Res 4:73-78, 1981.

275. Muscettola G, Potter WZ, Gordon EK, Goodwin FK: Methodological issues in the measurement of urinary MHPG. Psychiatry Res 4:267-276, 1981.

276. Gold PW, Goodwin FK, Post RM, Robertson GL: Vasopressin function in depression and mania [proceedings]. Psychopharmacol Bull 17:7-9, 1981.

277. Potter WZ, Calil HM, Extein I, Muscettola G, Goodwin FK: Crossover study of zimelidine and desipramine in depression: Evidence for amine specificity. Psychopharmacol Bull 17:26-29, 1981.

278. Extein I, Pickar D, Gold MS, Gold PW, Pottash ALC, Sweeney DR, Ross RJ, Rebard R, Martin D, Goodwin FK: Methadone and morphine in depression. Psychopharmacol Bull 17:29-33, 1981.

279. Brown GL, Goodwin FK, Ballenger JD, Goyer PF: Cerebrospinal fluid amine metabolites and cyclic nucleotides in human aggression. Psychopharmacol Bull 17:63-65, 1981.

280. Pickar D, Naber D, Post RM , van Kammen DP, Ballenger J, Cohen RM, Rubinow D, Waters RN, Goodwin FK, Bunney WE Jr: Cerebrospinal fluid endorphins in psychiatric patients. Psychopharmacol Bull 17:76-78, 1981.

281. Jimerson DC, Ballenger JC, Lake CR, Post RM, Goodwin FK, Kopin IJ: Plasma and CSF MHPG in normals. Psychopharmacol Bull 17:86-87, 1981.

282. Weingartner H, Gold P, Ballenger JC, Smallberg SA, Summers R, Rubinow DR, Post RM, Goodwin FK: Effects of vasopressin on human memory functions. Science 211:601-603, 1981.

283. Crawley JN, Marangos PJ, Paul SM, Skolnick P, Goodwin FK: Interaction between purine and benzodiazepine: Inosine reverses diazepam-induced stimulation of mouse exploratory behavior. Science 211:725-727, 1981.

284. Wehr TA, Goodwin FK: Stress, circadian rhythms and affective disorder. In: Stress and Coping I: Psychophysiology. Report No 3. Philadelphia: Smith, Kline and French, 1981.

285. Goodwin FK, Wirz-Justice A, Wehr TA: Evidence that the pathophysiology of depression and the mechanism of action of antidepressant drugs both involve alterations in circadian rhythms. In: E Costa, G Racagni, eds: Advances in Biochemical Psychopharmacology. Vol 32. Typical and Atypical Antidepressants: Clinical Practice. New York: Raven Press, 1982. pp 1-11.

286. Brown GL, Goodwin FK, Bunney WE: Human aggression and suicide: Their relationship to neuropsychiatric diagnoses and serotonin metabolism. Adv Biochem Psychopharmacol 34:287-307, 1982.

287. Goodwin FK, Prange AJ Jr, Post RM, Muscettola G, Lipton MA: Potentiation of antidepressant effects by L-triiodothyronine in tricyclic nonresponders. Am J Psychiatry 139:34-38, 1982.

288. Brown GL, Ebert MH, Goyer PF, Jimerson DC, Klein WJ, Bunney WE, Goodwin FK: Aggression, suicide, and serotonin: Relationships to CSF amine metabolites. Am J Psychiatry 139:741-746, 1982.

289. Rosenthal NE, Goodwin FK: The role of the lithium ion in medicine. Ann Rev Med 33:555-568, 1982.

290. Potter WZ, Murphy DL, Wehr TA, Linnoila M, Goodwin FK: Clorgyline: A new treatment for patients with refractory rapid-cycling disorder. Arch Gen Psychiatry 39:505-510, 1982.

291. Wehr TA, Goodwin FK, Wirz-Justice A, Breitmaier J, Craig C: 48-hour sleep- wake cycles in manic-depressive illness: Naturalistic observations and sleep deprivation experiments. Arch Gen Psychiatry 39:559-565, 1982.

292. Gold PW, Rubinow D, Post RM, Goodwin FK: Central peptides in psychiatric research. In: R Collu, JR Ducharme, A Barbeau, G Tolis, eds: Brain Neurotransmitters and Hormones. New York: Raven Press, 1982. pp 221-239.

293. Patel J, Marangos PJ, Stivers J, Goodwin FK: Characterization of adenosine receptors using N6 cyclohexyl [_H] adenosine. Brain Res 237:203-214, 1982.

294. Donnelly EF, Murphy DL, Goodwin FK, Waldman IN: Intellectual function in primary affective disorder. Br J Psychiatry 140:633-636, 1982.

295. Potter WZ, Calil HM, Sutfin TA, Zavadil AP, Jusko WJ, Rapoport J, Goodwin FK: Active metabolites of imipramine and desipramine in man. Clin Pharm Ther 31:393-401, 1982.

296. Pickar D, Extein I, Gold PW, Summers R, Naber D, Goodwin FK: Endorphins and affective illness. In: NS Shah, AG Donald, eds: Endorphins and Opiate Antagonists in Psychiatric Research: Clinical Implications. New York: Plenum Medical Book Co, 1982. pp 375-397.

297. Zis AP, Goodwin FK: The amine hypothesis. In: Paykel ES, ed: Handbook of Affective Disorders. London: Churchill Livingstone Press, 1982. pp 175-190.

298. Paul SM, Marangos PJ, Skolnick P, Goodwin FK: Biological substrances of anxiety: Benzodiazepine receptors and endogenous ligands. LÕEncephale 8:131-144, 1982.

299. Post RM, Gold P, Rubinow DR, Ballenger JC, Bunney WE Jr, Goodwin FK: Peptides in the cerebrospinal fluid of neuropsychiatric patients: An approach to central nervous system peptide function. Life Sci 31:1-15, 1982.

300. Goodwin FK: Special issues in lithium treatment of recurrent affective illness. In KR Jamison, ed: Lithium: Clinical Considerations. Amsterdam: Exerpta Medica, 1982. pp 33-40.

301. Goodwin FK: Depression and manic-depressive illness. In: Medicine for the Layman. Washington, DC: U.S. Government Printing Office, 1982. pp 5-29.

302. Crawley JN, Marangos PJ, Stivers J, Goodwin FK: Chronic clonazepam administration induces benzodiazepine receptorsubsensitivity. Neuropharmacology 21:85-89, 1982.

303. Karoum F, Linnoila M, Potter WZ, Chuang LW, Goodwin FK, Wyatt RJ: Fluctuating high urinary phenylethylamine excretion rates in some bipolar affective disorder patients. Psychiatry Res 6:215-222, 1982.

304. Linnoila M, Lamberg B-A, Potter WZ, Gold PW, Goodwin FK: High reverse T3 levels in manic and unipolar depressed women. Psychiatry Res 6:271-276, 1982.

305. Lewy AJ, Wehr TA, Rosenthal NE, Nurnberger JI, Siever LJ, Uhde TW, Newsome DA, Becker LE, Markey SP, Kopin IJ, Goodwin FK: Melatonin secretion as a neurobiological "marker" and effects of light in humans. Psychopharmacol Bull 18:127-129, 1982.

306. Brown GL, Goodwin FK, Bunney WE Jr: Human aggression and suicide: Their relationship to neuropsychiatric diagnoses serotonin metabolism. In: BT Ho, E Usdin, E Costa, eds: Serotonin in Biological Psychiatry. New York: Raven Press, 1982. pp 287-307.

307. Wehr TA, Gillin JS, Goodwin FK: Sleep and circadian rhythms in depression. In: M Chase, ED Weitzman, eds: Advances in Sleep Research. Vol 8. SleepDisorders: Basic and Clinical Research. New York: Spectrum Publication, 1983. pp 195-225.

308. Wehr TA, Wirz-Justice A, Goodwin FK: Circadian rhythm disturbances in affective illness and their modification by antidepressant drugs. In: JM Davis, JW Maas, eds: Affective Disorders. Washington, DC: American Psychiatric Press, 1983. pp 333-346.

309. Cowdry RW, Wehr TA, Zis AP, Goodwin FK: Thyroid abnormalities associated with rapid-cycling bipolar illness. Arch Gen Psychiatry 40:414-420, 1983.

310. Linnoila M, MacDonald E, Reinila M, Leroy A, Rubinow DR, Goodwin FK: RBC membrane adenosine triphosphatase activities in patients with major affective disorders. Arch Gen Psychiatry 40:1021-1026, 1983.

311. Cowdry RW, Ebert MH, van Kammen DP, Post RM, Goodwin FK: Cerebrospinal fluid probenecid studies: A reinterpretation. Biol Psychiatry 18:1287-1299, 1983.

312. Goodwin FK, Post RM: 5-hydroxytryptamine and depression: A model for the interaction of normal variance with pathology. Br J Clin Pharmacol 15 (Suppl 3):393S-405S, 1983.

313. Wehr TA, Goodwin FK: Introduction. In: TA Wehr, FK Goodwin, eds: Circadian Rhythms in Psychiatry. Pacific Grove, CA: The Boxwood Press, 1983. pp 1-15.

314. Wehr TA, Goodwin FK: Biological rhythms in manic-depressive illness. In: TA Wehr, FK Goodwin, eds: Circadian Rhythms in Psychiatry. Pacific Grove, CA: The Boxwood Press, 1983. pp 129-184.

315. Insel TR, Goodwin FK: The dexamethasone suppression test: Promises and problems of diagnostic laboratory tests in psychiatry. Hosp Community Psychiatry 34:1131-1138, 1983.

316. Gold PW, Robertson GL, Post RM, Kaye W, Ballenger J, Rubinow D, Goodwin FK: The effect of lithium on the osmoregulation of arginine vasopressin secretion. J Clin Endocrinol Metab 56:295-299, 1983.

317. Gold PW, Robertson GL, Ballenger JC, Kaye W, Chen J, Rubinow DR, Goodwin FK, Post RM: Carbamazepine diminishes the sensitivity of the plasma arginine vasopressin response to osmotic stimulation. J Clin Endocrinol Metab 57:952-957, 1983.

318. Linnoila M, Virkkunen M, Scheinin M, Nuutila A, Rimon R, Goodwin FK: Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from non impulsive violent behavior. Life Sci 33:2609-2614, 1983.

319. Goodwin FK: The impact of tricyclic antidepressants and lithium on the course of recurrent affective disorders. McLean Hosp J 8:1-16, 1983.

320. Potter WZ, Muscettola G, Goodwin FK: Sources of variance in clinical studies of MHPG. In: JW Maas, ed: MHPG: Basic Mechanisms and Psychopathology. New York: Academic Press, 1983. pp 145-165.

321. Post RM, Gold PW, Rubinow DR, Bunney WE Jr, Ballenger JC, Goodwin FK: Cerebrospinal fluid as neuroregulatory pathway: Peptides in neuropsychiatric illness. In: JH Wood, ed: The Neurobiology of Cerebrospinal Fluid. Vol 2. New York: Plenum Press, 1983. pp 107-141.

322. Ballenger JC, Post RM, Goodwin FK: Neurochemistry of cerebrospinal fluid in normal individuals: Relationship between biological and psychological variables. In: JH Wood, ed: The Neurobiology of Cerebrospinal Fluid. Vol 2. New York: Plenum Press, 1983. pp 143-155.

323. Rosenthal NE, Lewy AJ, Wehr TA, Kern HE, Goodwin FK: Seasonal cycling in a bipolar patient. Psychiatry Res 8:25-31, 1983.

324. Gold PW, Robertson GL, Ballenger JC, Goodwin FK, Rubinow DR, Kellner C, Post RM: Neurohypophyseal function in affective illness. Psychopharmacol Bull 19:426-431, 1983.

325. Jamison KR, Goodwin FK: Psychotherapeutic treatment of manic-depressive patients on lithium. In: MH Greenhill, A Gralnick, eds: Psychopharmacology and Psychotherapy. New York: Free Press, 1983. pp 53-77.

326. Goodwin FK: Special issues in the treatment of recurrent affective illness. Strecker Monograph #20. The Institute of Pennsylvania Hospital, Philadelphia, Pennsylvania, 1983. (Strecker Award Paper)

327. Goodwin FK: The biology of depression: Conceptual issues. In: Usdin E, M Asberg, L Bertilsson, F Sjšqvist, eds: Advances in Biochemical Psychopharmacology, Vol. 39: Frontiers in Biochemical and Pharmacological Research in Depression. Nobel Conference Paper. New York: Raven Press, 1984. pp 11-26.

328. Brown GL, Goodwin FK: Aggression, adolescence, psycho-biology. In: CR Keith, ed: The Aggressive Adolescent. New York: The Free Press, 1984. Pp 63-95.

329. Ninan PT, van Kammen DP, Scheinin M, Linnoila M, Bunney WE Jr, Goodwin FK: CSF 5-hydroxyindoleacetic acid levels in suicidal schizophrenic patients. Am J Psychiatry 141:566-569, 1984.

330. Muscettola G, Potter WZ, Pickar D, Goodwin FK: Urinary 3-methoxy-4- hydroxyphenylglycol and major affective disorders: A replication and new findings. Arch Gen Psychiatry 41:337-342, 1984.

331. Rosenthal NE, Sack DA, Gillin JC, Lewy AJ, Goodwin FK, Davenport Y, Mueller PS, Newsome DA, Wehr TA: Seasonal affective disorder: A description of the syndrome and preliminary findings with light therapy. Arch Gen Psychiatry 41:72-80, 1984.

332. Goodwin FK, Jamison KR: The natural course of manic-depressive illness. In: RM Post, JC Ballenger, eds. Neurobiology of Mood Disorders. Baltimore: Williams & Wilkins, 1984. pp 20-37.

333. Gold PW, Ballenger JC, Robertson GL, Weingartner H, Rubinow DR, Hoban MC, Goodwin FK, Post RM: Vasopressin in affective illness: Direct measurement, clinical trials, and response to hypertonic saline. In: RM Post, JC Ballenger, eds: Neurobiology of Mood Disorders. Baltimore: Williams & Wilkins, 1984. pp 323-339.

334. Post RM, Jimerson DC, Ballenger JC, Lake CR, Uhde TW, Goodwin FK: Cerebrospinal fluid norepinephrine and its metabolites in manic-depressive illness. In: RM Post, JC Ballenger, eds: Neurobiology of Mood Disorders. Baltimore: Williams & Wilkins, 1984. pp 539-553.

335. Paul SM, Rehavi M, Skolnick P, Goodwin FK: High affinity binding of antidepressants to biogenic amine transport sites in human brain and platelet: Studies in depression. In: RM Post, JC Ballenger, eds: Neurobiology of Mood Disorders. Baltimore: Williams & Wilkins, 1984. pp 846-853.

336. Strupp B, Weingartner H, Goodwin FK, Gold PW: Neuro-hypophyseal hormones and cognition. Pharmacol Ther 23:267-279, 1984.

337. Insel TR, Goodwin FK: The dexamethasone suppression test as a predictor of relapse. In: RMA Hirschfeld, SH Koslow, DJ Kupfer, eds: Clinical Utility of the Dexamethasone Suppression Test. Proceedings of a National Institute of Mental Health Workshop, July 1982. Washington, DC: US Government Printing Office, 1985. pp 41-43.

338. Hauger R, Luu HMD, Goodwin FK, Paul SM: Characterization of [_H]ouabain binding sites in human brain, platelet, and erythrocyte. J Neurochem 44:1704- 1708, 1985.

339. Hauger R, Luu HMD, Meyer DK, Goodwin FK, Paul SM: Characterization of "high affinity" [_H] ouabain binding in the rat central nervous system. J Neurochem 44:1709-1715, 1985.

340. Wehr TA, Sack DA, Duncan WC, Mendelson WB, Rosenthal NE, Gillin JC, Goodwin FK: Sleep and circadian rhythms in affective patients isolated from external time cues. Psychiatry Res 15:327-339, 1985.

341. Pincus HA, Fine T, Pardes H, Goodwin FK: The animal rights movement: A research perspective. Am J Psychiatry 143:1585-1586, 1986.

342. Brown GL, Goodwin FK: Cerebrospinal fluid correlates of suicide attempts and aggression. Ann NY Acad Sci 487:175-188, 1986.

343. Goodwin FK: Suicide, aggression, and depression: A theoretical framework for future research. Ann NY Acad Sci 487:351-355, 1986.

344. Barbaccia ML, Costa E, Ferrero P, Guidotti A, Roy A, Sunderland T, Pickar D, Paul SM, Goodwin FK: Diazepam-binding inhibitor: A brain neuropeptide present in human spinal fluid: Studies in depression, schizophrenia, and AlzheimerÕs disease. Arch Gen Psychiatry 43:1143-1147, 1986.

345. Brown GL, Kline WJ, Goyer PF, Minichiello MD, Kreusi MJP, Goodwin FK: Relationship of childhood characteristics to cerebrospinal fluid 5-hydroxyindoleacetic acid in aggressive adults. C Shagass, RC Josiassen, WH Bridger, KJ Weiss, D Stoff, GM Simpson, eds: Biological Psychiatry 1985. New York: Elsevier, 1986. pp 177-179.

346. Goodwin FK, Roy-Byrne P: Research careers in biological psychiatry. In: HA Pincus, H Pardes, eds: Clinical Research Careers in Psychiatry. Washington, DC: American Psychiatric Press, Inc, 1986. pp 13-23.

347. Strupp B, Weingartner H, Goodwin FK, Gold PW: Neurohypophypeal hormones and cognition. In: D de Wied, WH Gispen, TB van Wimersma Greidanus, eds: International Encyclopedia of Pharmacology and Therapeutics, Section 123: Neuropeptides and Behavior, Vol. 2: The Neurohypophypeal Hormones. Oxford: Pergamon Press, 1986. pp 157-169.

348. Goodwin FK, Brown GL: Biological correlates of human aggression and suicide. Intl J Neurosci 31:252, 1986.

349. Janowsky DS, Glick ID, Lash L, Mitnick L, Klein DF, Goodwin FK, Hanin I, Nemeroff C, Robins L: Psychobiology and psychopharmacology: Issues in clinical research training. J Clin Psychopharm 6:1-7, 1986.

350. Goodwin FK: Pharmacological consultation in major depressive disorders. In: DC Jimerson, JP Docherty, eds: Psychopharmacology Consultation. Washington, DC: American Psychiatric Press, 1986. pp 2-17.

351. Brown GL, Goodwin FK: Human aggression and suicide: Suicide Life Treat Behav 16:223- 243, 1986.

352. Brown GL, Goodwin FK: Human aggression: A biological perspective. In: WH Reid, D Dorr, JI Walker, JW Bonner, eds: Unmasking The Psychopath: Antisocial Personality and Related Syndromes. New York: WW Norton, 1986. pp 132-155.

353. Wehr TA, Goodwin FK: Can antidepressants cause mania and worsen the course of affective illness? Am J Psychiatry 144: 1403-1411, 1987.

354. Virkkunen M, Nuutila A, Goodwin FK, Linnoila M: Cerebrospinal fluid monoamine metabolite levels in male arsonists. Arch Gen Psychiatry 44:241-247, 1987.

355. Goodwin FK: Recent advances in understanding and treating manic-depressive illness. In: JE Hamner, BR Jennings, eds: The 1986 Distinguished Visiting Professorship Lectures. Memphis: University of Tennessee, The Health Science Center, 1987. pp 11-27.

356. Kling MA, Goodwin FK, Gold PW: Commentary on actions of steroids on neuron: Role in personality, mood, stress, and disease. Integr Psychiatry 5:271- 273, 1987.

357. Potter WZ, Rudorfer MV, Goodwin FK: Biological findings in bipolar disorders. In: RE Hales, AJ Francis, eds: Psychiatry Update: American Psychiatric Association Annual Review. Vol. 6. Washington, DC: American Psychiatric Press, Inc, 1987. pp 32-60.

358. Wehr TA, Sack DA, Rosenthal NE, Goodwin FK: Sleep and biological rhythms in bipolar illness. In: RE Hales, AJ Francis, eds: Psychiatry Update: American Psychiatric Association Annual Review. Vol 6. Washington, DC, 1987. pp 61-80.

359. Goodwin FK, Roy-Byrne P: Treatment of bipolar disorders. In: RE Hales, AJ Frances, eds: Psychiatry Update: The American Psychiatric Association Annual Review. Vol 6. Washington, DC: American Psychiatric Press, Inc, 1987. pp 81-107.

360. Wehr TA, Goodwin FK: Do antidepressants cause mania? Psychopharmacol Bull 23:61-65, 1987.

361. Goodwin FK, Roy-Byrne PP: Future directions in biological psychiatry. In: HY Meltzer, ed: Psychopharmacology: The Third Generation of Progress. New York: Raven Press, 1987. pp 1691-1698.

362. Wehr TA, Goodwin FK: Reply: Antidepressants and mania. Am J Psychiatry 145:906-907, 1988.

363. Regier DA, Hirschfeld RMA, Goodwin FK, Burke JD Jr, Lazar JB, Judd LL: The NIMH Depression Awareness, Recognition, and Treatment Program: Structure, aims and scientific basis. Am J Psychiatry 145:1351-1357, 1988.

364. Hirschfeld RMA, Goodwin FK: Mood disorders. In: JA Talbott, RE Hales, SC Yudofsky, eds: American Psychiatric Press Textbook of Psychiatry. Washington, DC: American Psychiatric Press, Inc, 1988. pp 403-441.

365. Jeste DV, Lohr JB, Goodwin FK: Neuroanatomical studies of major affective disorders: A review and suggestions for further research. Br J Psychiatry 153: 444-459, 1988.

366. Gold PW, Goodwin FK, Chrousos GP: Clinical and biochemical manifestations of depression: Relation to the neurobiology of stress. Part I. N Engl J Med 319:348-353, 1988.

367. Gold PW, Goodwin FK, Chrousos GP: Clinical and biochemical manifestations of depression: Relation to the neurobiology of stress. Part II. N Engl J Med 319: 413-420, 1988.

368. Goodwin FK: AIDS and the brain: Origins, manifestations, and possible treatment and prevention strategies. Psychopharmacol Bull 24:305-306, 1988.

369. Goodwin FK, Bridge TP, Ingraham LJ: Perspectives on the evolution of federal AIDS research policy. Psychopharmacol Bull 24:330-333, 1988.

370. Pincus HA, Goodwin FK, Barchas JD, Cohen DJ, Judd LL, Meltzer HY, Vaillant GE: The future of the science of psychiatry. In: JA Talbott, ed: Future Directions for Psychiatry. Washington, DC: American Psychiatric Press, 1989. pp 75-106.

371. Goodwin FK: The biology of recurrence: New directions for the pharmacologic bridge. J Clin Psychiatry 50(Suppl):40-44, 1989.

372. Virkkunen M, DeJong J, Bartko J, Goodwin FK, Linnoila M: Relationship of psychobiological variables to recidivism in violent offenders and impulsive fire setters: a follow-up study. Arch Gen Psychiatry, 1989, 46:600-603.

373. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK: Comorbidity of mental disorders with alcohol and other drug abuse: Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 264:2511-2518, 1990.

374. Goodwin FK: Il futuro della psicofarmacologia. In: CA Altamura, G Gnocchi, P Monteleone, G Muscettola, eds: Psicofarmacoresistenza: Problemi EProspettive. Napoli: Collana Di Neurologia E Psichiatria, Casa Editrice Libraria Idelson, 1990. pp 3-16.

375. Brown GL, Linnoila M, Goodwin FK: Clinical assessment of human aggression and impulsivity in relationship to biochemical measures. In: HM van Pragg, R Plutchik, A Apter, eds: Violence and Suicidality: Perspectives in Clinical and Psychobiological Research. New York: Brunner/Mazel, 1990. pp 184-217.

376. Goodwin FK: The price of progress. In: DC Harrison, M Osterweis, ER Rubin, eds: Preparing for Science in the 21st Century. Washington, DC: Association of Academic Health Centers, 1991. pp 86-96.

377. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK: Association entre troubles mentaux, alcoholism et toxicomanie: RŽsultats de lÕEpidemiological Catchment Area (ECA) Study. JAMA H 3:37-39, 1991.

378. Vocci FJ, Goodwin FK: Risks associated with benzodiazepine use and abuse. In: HY Meltzer, D Nerozzi, eds: Current Practices and Future Developments in the Pharmacotherapy of Mental Disorders. Amsterdam: Excerpta Medica, 1991. pp. 223-231.

380. Goodwin FK, Runck BL: Suicide intervention: Integration of psychosocial, clinical, and biomedical traditions. In: D Jacobs, ed: Suicide and Clinical Practice. Washington, DC: American Psychiatric Press, Inc., 1992. pp. 1-21.

381. Brown GL, Linnoila MI, Goodwin FK: Impulsivity, aggression, and associated affects: Relationship to self-destructive behavior and suicide. In R Maris, ed: Assessment and Prediction of Suicide. New York: Guilford Press, 1992. pp. 589-606.

382. Regier DA, Farmer ME, Goodwin FK: Comorbidity of mental and substance abuse disorders. In R Michels et al., eds: Psychiatry. Philadelphia: J.B. Lippincott Co., 1992. Chapter 17.1, pp. 1-23.

383. Goodwin FK: The ethics of using animals in stress research. In R Kvetnansky, R McCarty, J Axelrod, eds: Stress: Neuroendocrine and Molecular Approaches, Vol. II. Philadelphia: Gordon and Breach Science Publishers, 1992. pp 1009- 1027.

384. Goodwin FK: Animal research, animal rights, and human health: The 60th Stephen Paget Memorial Lecture (11/22/1991). Conquest - Journal of the Research Defense Society, No. 181, August 1992. pp. 1-10.

385. Goodwin FK: Animal Rights: Medical research and product testing: Is this a "hang together or together we hang" issue? Contemporary Topics in Laboratory Animal Science 31 (1):6-11, 1992.

386. Mann JJ, Goodwin FK, OÕBrien CP, Robinson DS: Suicidal behavior and psychotropic medication. Accepted as a consensus statement by the ACNP Council, March 2, 1992, Neuropsychopharmacology 8:177-183, 1993.

387. Rudorfer MV, Goodwin FK: Introduction. In CE Coffey, ed: The Clinical Science of Electroconvulsive Therapy. Washington, DC: American Psychiatric Press, Inc., 1993. pp. xvii-xxi.

388. Regier DA, Narrow WE, Rae DS, Manderschied RW, Locke BZ, Goodwin FK: The de facto U.S. mental and addictive disorders service system: ECA prospective one-year prevalence rates of disorders and services. Arch Gen Psychiatry 50:85-94, 1993.

389. Goodwin FK: Predictors of Antidepressant Response. Bul Menninger Clinic 57(2):146-160, 1993.

390. Goodwin FK: New directions for NIMH. The National Forum-The Phi Kappa Phi Journal 73(1):31-33, 1993.

391. Goodwin FK: Neurobiology of manic-depressive illness: The next chapter. Clinical Neuroscience: Topical Reviews on Research and Treatment. 1:157-162, 1993.

392. Goodwin FK: Mental illness in health care reform. The National Forum-The PhiKappa Phi Journal 73(3):31-33, 1993.

393. Goodwin FK, Blehar MC: Introduction -- Special edition: Towards a new psychobiology of depression in women. J Affective Disorders 29:75-76, 1993.

394. Goodwin FK: The cost of affective illness: Through a clinical lens. Brit J Psychiatry (Suppl). In press, 1994.

395. Goodwin FK: Psychiatry -- 1994. JAMA 271:1707-1708, 1994

396. Goodwin FK: Introduction -- Special Issue: Federal medications development programs: A novel approach to providing needed pharmacotherapies. Psychopharmacol Bull 30(1): in press, 1994.

397. Goodwin FK: Introduction -- Special Issue: New directions for ECT research Psychopharmacol Bull 30(4): in press, 1994.

398. Goodwin FK: The National Institute of Mental Health. In B. Wolman, ed: Encyclopedia of Psychology, Psychiatry and Psychoanalysis. New York: Henry Holt. In press, 1994.

399. Goodwin FK: Mental health: 1993. Americana Annual. Danbury, CT: Grolier, 1994.

400. Tohen M. and Goodwin FK: Epidemiology of bipolar disorder. In Tsuang et al., eds: Textbook in Psychiatric Epidemiology. Wiley-Liss, Inc., 1995. Chapter 15:pp 301-315.

401. Goodwin FK: The etiology of affective disorders. In: M Ackenheil and B Bondy, eds.: Proceedings of the International Symposium in Honour of Professor Dr. Hanns Hippius: Implications of Psychopharmacology to Psychiatry: Biological, Nosological, and Therapeutical Concepts. 1995.

402. Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, Keller M, Warshaw M, Clayton P, Goodwin FK: Switching from ÔUnipolarÕ to Bipolar II: Arch Gen Psychiatry, 1995 52:114-123.

403. Gabbard GO, Goodwin FK: Integrating Biological and Psychosocial Perspectives. In: LJ Dickstein, MB Riba, JM Oldham, eds: Review of Psychiatry,Washington, DC, 1996. pp. 527-548.

404. Goodwin FK: Clinical Crossroads: A 47-Year-Old Man With Chronic Depression. JAMA 1996, 275: 479-485.

405. Goodwin FK: The Etiology of Affective Illness. In: M. Ackenheil, B. Bondy, R. Engel, M. Ermann and N. Nedopil, eds: Implications of Psychopharmacology to Psychiatry. Germany: Springer, 1996. pp. 13-22.

406. Bowden CL, Brady KT, Forster PL, Goodwin FK, Tohen M, Golanty SA, Sharp DL: Current Concepts in Treating Bipolar Disorder: Journal of Clinical Psychiatry, March 1996. pp 1-12. (suppl)

407. Goodwin FK, Hadley SW: Enhancing the climate of trust in clinical psychiatric research. In AE Shamoo, ed: Ethics in Neurobiological Research with Human Subjects: The Baltimore Conference on Ethics. The Netherlands: Gordon and Breach Science Publishers, 1997. pp. 309-314.

408. Goodwin FK, Ghaemi SN: Prospects for a scientific psychiatry. Acta Neuropsychiatrica 1997 9:49-51.

409. Goodwin FK, Ghaemi SN. Future directions in mood disorder research. In: Honig A, van Praag HM, eds: Depression: Neurobiological, Psychopathological, and Therapeutic Advances. London: John Wiley and Sons, Ltd., 1997. pp. 627-643.

410. Goodwin FK, Ghaemi SN. Understanding manic-depressive illness. Archives of General Psychiatry. 1998; 55:23-25.

411. Ghaemi SN, Katzow JJ, Desai SM, Goodwin FK. Gabapentin treatment of mood disorders: a preliminary study. Journal of Clinical Psychiatry, 1998 59:426-429

412. Ghaemi SN, Ziegler DM, Peachey TJ, Goodwin FK. Cost-effectiveness of clozapine therapy for severe psychosis. Psychiatric Services. 1998 49: 829-31.

413. Goodwin FK. The return of NIMH to NIH and the fight for parity. American Journal of Psychiatry. V1 55:9, 1998 (suppl)

414. Ghaemi SN, Boiman EE, Goodwin FK. Kindling and second messengers: An approach to the neurobiology of recurrence in bipolar disorder. Biological Psychiatry, 1999 45: 137-144

415. Ghaemi SN, Goodwin FK. The use of Atypical antipsychotic agents in Bipolar and Schizoaffective Disorders. Journal of Clinical Psychopharmacology, 1999 19:354-361

416. Ghaemi SN, Sacks GS, Chiou AM, Pandurangi AK, Goodwin, FK. Is bipolar disorder underdiagnosed? Are antidepressants overutilized? Journal of Affective Disorders, 1999 52: 135-144

417. Goodwin FK, Ghaemi SN. Introduction and Historical Review of Mood Disorders. Oxford Textbook of Psychiatry, London: Oxford University Press, 1999.

418. Ghaemi SN, Boiman EE, Goodwin FK. Insight and Outcome in Bipolar, Unipolar and Anxiety Disorders. Comprehensive Psychiatry, 1999

419. Goodwin FK. Neurobiology of Recurrent Affective Illness, Taiwanese Journal Psychiatry, March 1998 Vol 12, 1:3-14

420. Goodwin FK, Ghaemi SN. Bipolar Disorder - State of the Art. Dialogues in Clinical Neuroscience, 1999 1:41-51.

421. Goodwin FK. Anticonvulsant Therapy and Suicide Risk in Affective Disorders. Journal of Clinical Psychiatry. 60 Suppl 2:89-93, 1999.

422. Goodwin FK. Lee, MR.; Cohen, L.; Hadley, SW. Cognitive- Behavioral Group Therapy With Medication for Depressed Gay Men With AIDS or Symptomatic HIV Infection. Psychiatric Services, 1999.

423. Goodwin FK and Ghaemi SN: The Impact of Mood Stabilizers on Suicide in Bipolar Disorder: A Comparative Analysis. Primary Psychiatry, September, 1999, 61-66.

424. Goodwin FK, Ghaemi SN. The Impact of the Discovery of Lithium on Psychiatric Thought and Practice in the U.S. and Europe. Australian and New Zealand Journal of Psychiatry, December 1999: Vol 33 (suppl.)

425. Goodwin FK, Ghaemi SN. The Impact of Mood Stabilizers on Suicide in Bipolar Disorder: A Comparative Analysis. CNS Spectrums Ð The International Journal of Neuropsychiatric Medicine Feb. 2000: Vol 5 #2 (suppl 1)

426. Goodwin, FK: Foreword. In: Fawcett J, Golden B, Rosenfeld N. New Hope for People with Bipolar Disorder. Roseville, CA: Prima Publishing, 2000.

427. Ghaemi SN, Shields GS, Hegarty JD, Goodwin FK. Cholesterol levels in mood disorders: high or low? Bipolar Disorders, 2000: 2, 60-64

428. Ghaemi SN, Boiman EE, Goodwin FK. Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. J Clin Psychiatry, 2000

429. Ghaemi SN, Goodwin FK, Sachs GS. What is to be done? Controversies in the diagnosis and treatment of manic-depressive illness. World J of Biol Psychiatry. 2000: 2, 65-74.

430. Ghaemi SN, Goodwin FK. Long-term naturalistic treatment of depressive symptoms in bipolar illness with divalproex vs. lithium in the setting of minimal antidepressant use. J of Affective Disorders, 2001: 65, 281-287.

431. Goodwin, FK: Foreword. In: Burrows G and Milgrom J. Psychology and Psychiatry: Integrating Medical Practice. Chicester, UK: John Wiley and Sons March 2001.

432. Ghaemi SN, Goodwin FK. Gabapentin treatment of the non-refractory bipolar spectrum: an open case series. J of Affective Disorders. 2001: 65, 167-171.

433. Goodwin FK, Ghaemi SN. The difficult-to-treat patient with bipolar disorder. In Dewan, MJ and Pies, RW eds., The Difficult-to-Treat Psychiatric Patient, Washington, DC, 2001. p. 7-39.

434. Goodwin FK, Ghaemi SN. The bipolar spectrum and the antidepressant view of the world. J of Psychiatric Practice. 2001:5(7), 287-301.

435. Ghaemi SN, Kirkwood C, Sambur MR, Ko JY, Howden K, Duong QV, and Goodwin FK. Economic Outcomesof Risperidone in Comparison to Typical Neuroleptic Agents for Treatment Resistant Psychosis: A Community Based Study. Journal Pharm Technol. 2001;17:273-8

436. Ghaemi SN, Ko JY, Goodwin FK. "CadeÕs Disease" and Beyond: Misdiagnosis, Antidepressant Use, and a Proposed Definition for Bipolar Spectrum Disorder. Canadian Journal of Psychiatry 2002;47:125-34.

437. Ghaemi SN, Ko JY, Goodwin FK. Diagnostico erroneo, empleo de antidepresivos y transtorno del espectro bipolar. Palomo T, Beninger RJ, Jimenez-Arriero MA, Huertas E, editors, El Espectro Bipolar. Madrid: Espana: Fundacion Cerebro y Mente. 2002; pp. 35-57.

438. Goodwin FK. Rationale for long-term treatment of bipolar disorder and evidence for long-term lithium treatment. J Clin Psychiatry, 2002; 63 (suppl 10)

439. Calabrese JR, Sullivan JR, Bowden CL, Suppes T, Goldberg JF, Sachs GS, Shelton MD, Goodwin FK, Frye MA, Kusumakar V. Rash in Multicenter Trials of Lamotrigine in Mood Disorders: Clinical Relevance and Management. J Clin Psychiatry, 2002; 63:11, pp.1012-1019.

440. "Management of bipolar disorder" in: Dunner DL, Baldessarini RJ, DePaulo JR, Fawcett JA, Goodwin FK, Grof P, Manji, HK. Achieving success in the management of bipolar disorder: is lithium sufficient?" J Clin Psychiatry Visuals, 2003.

441. Goodwin FK. Preventing Inpatient Suicide. J Clin Psychiatry, 2003; 64:1, pp. 12- 13.

PARTIAL LIST OF OTHER PUBLICATIONS (Not including book reviews)

1. Goodwin FK: Interview: What causes mental depression and how to cope. In US News and World Report, October 8, 1979.

2. Goodwin FK: Letter to the Editor: Psychiatry and the Law, responding to columnist George Will. In The Washington Post, June 1982.

3. Goodwin FK: Letter to the Editor, responding to Richard Restak on psychiatric diagnoses. In The Washington Post, July 22, 1985.

4. Goodwin FK: Essay: AmericaÕs Psychological Wound Has Never Healed. Commentary on the 25th anniversary of President KennedyÕs death. The Washington Post, Outlook, November 13, 1988.

5. Goodwin FK: Interview: Animal research versus humane use: The struggle to sustain our research advances. The FASEB Journal 3:2455-2456; 2563-2564, 1989.

6. Goodwin FK: Commentary: We canÕt sacrifice people for the sake of animal life. Newsday, Sunday May 21, 1989.

7. Goodwin FK: The value of animals in alcohol-related research. Alcohol Health and Research World 14(3):173-177, 1990.

8. Goodwin FK: Decade of the Brain. U.S. Medicine, March 1991.

9. Goodwin FK: Animal research and animal rights: Responsibilities of the scientific community. In: Animal Care and Use Programs: Regulatory Compliance and Education in an Age of Fiscal Constraint. Boston, MA: Public Responsibility in Medicine and Research (PRIM&R). Proceedings of a Conference, March 21-22, 1991.

10. Goodwin FK: Interview: Die Biologische Psychiatrie vor gro§en Aufgaben. In ZNS Journal, August 1, 1992. pp. 22-27.

11. Goodwin FK: DirectorÕs Column. Neuroscience Newsletter. Washington, DC: Society for Neuroscience, June 1994.

12. Goodwin FK: Presidential Column. The APS Observer. Washington, DC: American Psychological Society, May/June 1994.

13. Goodwin FK: Letter-to-the-Editor; lead letter responding to "Schizophrenia and psychiatryÕs limits." The Wall Street Journal, March 30, 1994, p. A-17.

14. Goodwin FK: Opinion/Editorial article: Journalistic psychobabble drives me crazy! (AuthorÕs title: LetÕs keep our leaders off of the couch.) In The Wall Street Journal, September 18, 1995.

15. Goodwin FK: Interview. Critical Review of Recent Developments in Clinical Psychopharmacology. Currents 16/1:5-11, January 1997.

16. Goodwin FK: Interview. Healthcare Policy and Managed Care: Critique and Recommendations. Currents 16/2:5-12, February 1997.

17. Goodwin FK and Morrison AM: Letter-to-the-Editor; letter responding to "A place for PETA at the science table?" The Washington Times, February 17, 1997, p. A-18.

18. Goodwin FK. Resolved: Medical Savings Accounts Will Improve Access to Mental Health Care Ð A Debate. 1999 American Psychiatric Association Annual Meeting Conference Summary, May 1999.

19. Goodwin FK and Ghaemi SN: Guest Editors Note. Primary Psychiatry September, 1999 p. 50.

20. Goodwin FK. Safe and Effective Drugs Have Improved the Lives of Millions. Psychology Today, October 1999, p. 41-42.

21. Goodwin FK: Opinion/Editorial Article. Scientists in Bunkers: How Appeasement of Animal Rights Activism Has Failed. Cerebrum, Fall 1999.

22. Goodwin FK: Interview. Identifying and Treating Comorbid Bipolar and Personality Disorders. Psychiatric TimesÕ Bipolar Disorders Letter. May 2000.

23. Goodwin, FK and Morrison AR: Opinion/Editorial Essay. Science and Self- Doubt: Why Animal Researchers Must Remember That Human Beings Are Special. Reason. October 2000.

24. Goodwin FK: Interview. Pharmacotherapy of Bipolar Disorder: Trends and Controversies. Currents. 20/1: 5-11, January 2001.

25. Goodwin FK: Interview. Award-Winning Research: Recognizing Frederick K. Goodwin, M.D. Psychiatric Times. 34-35, July 2001.

26. Goodwin FK and Goldberg R: Opinion/Editorial Essay. New Drugs: The Right Remedy. In The Washington Post. A21, July 7, 2001.

27. Goodwin FK, Horn S, and Goldberg R.: What Seniors Should Know About Government Restrictions on Prescription Drugs. In The Heritage Foundation Backgrounder. 1-6. November 4, 2002.

28. Goodwin FK, Baldessarini RJ, Dunner DL: Teaching Monograph. The Use of Lithium in Treating Bipolar Disorder. MedWorks Media, 2002.

29. Goodwin FK: Interview. Update on Treatment of Bipolar Depression (Part II). Currents. 22/1: 5-9, January 2003.

30. Goodwin FK: Interview. Update on Treatment of Bipolar Depression (Part III). Currents. 22/2: 5-8, February 2003.

A FEW EXAMPLES OF RECENT MEDIA INTERVIEWS AND APPEARANCES

1. Goodwin FK: Interview. Kids and Depression. In USA Today. November 30, 1999.

2. Goodwin FK: Interview. Six Signs that Could Save His Life. In Prevention. June 2000.

3. Goodwin FK: Interview. Most Presidents Had a Counselor. One Had a Shrink. In The New York Times. September 3, 2000.

4. Goodwin FK: Interview. Black Dog. "60 Minutes II." October 10, 2000.

5. Goodwin FK: Interview. Are You Secretly Sad? O Magazine. October 2000.

6. Goodwin FK: Interview. Gladys, Interrupted. Dateline NBC. June 4, 2001.

7. Goodwin FK: Interview. Moving. CNN Weekend. August 5, 2001.

8. Goodwin FK: Interview. On an Expedition Through the Mind. In The New York Times. August 12, 2001.

9. Goodwin FK: Interview. Prozac. NPR: The Diane Rehm Show. August 14, 2001.

10. Goodwin FK: Interview. True Life: IÕm Bipolar. MTV. July 2002.

11. Goodwin FK: Interview. Quit Paxil, And Then Zap! In The Washington Post. August 27, 2002.

Research Grants

2001 Solvay Pharmaceuticals, "The comparative impact of different mood stabilizer treatments on suicidal behavior in bipolar patients," Best Practice, LLC, Bethesda, MD and Kaiser Health Ssytem of Northern California, Oakland, California, principal investigator.

1999 Abbott Laboratories, Research on Children of Bipolar Parents

1997 Janssen Pharmaceutica, " Pharmacoeconomic review of risperidone use in psychotic disorders in Richmond," George Washington University, co-principal investigator

1997 Janssen Pharmaceutica, " The safety and efficiency of risperidone vs placebo vs haloperidol as add-on therapy to mood stabilizers in the treatment of the manic phase of bipolar disorder," George Washington University, co-principal investigator

1997 Glaxo-Wellcome, "A multicenter, double-blind, placebo-controlled, randomized, fixed-dose evaluation of the safety and efficacy of lamotrigine in the long-term prevention of relapse and recurrence of depression and/or mania in patients with bipolar I disorder," George Washington University, co-principal investigator

1997 Eli Lilly and Co., "Olanzapine added to mood stabilizers in the treatment of the manic phase of bipolar disorder," George Washington University, co- principal investigator